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A bbreviations
The abbreviations used in this thesis are in agreement with the recommendations of 
the editors of the Biochemical Journal ((1992) Biochem. J. 281, 1-19) with the 
following additions:
CA carrier ampholyte
CHAPS 3-[(cholamidopropyl) dimethylammonio]-l-
propansulphonate 
Gal galactose
GIcNAc N-acetylglucosamine
G i inhibitory guanine nucleotide binding regulatory protein
G s stimulatory guanine nucleotide binding regulatory protein
H B S S Hanks' balanced salt solution
HEPES A-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid
H S A B hydroxysuccinimidyl-p-azidobenzoate
IE F  isoelectric focusing
IPG  immobilised pH gradient
M PI mixture of protease inhibitors
N A P S CI 2-nitro-4-azidophenylsulphenyl chloride
PM SF phenylmethylsulphonyl fluoride
R s Stokes radius
TEMED A,A,A',A'-tetra methylethylenediamine
T H -glucagon [l-N-a-trinitrophenylhistidine, 12-homoarginine] glucagon
T N P-glucagon Na-Trinitrophenyl glucagon
TP A 12-o-tetradecanoylphorbol 13-acetate
WGA wheat germ agglutinin
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Summary
Treatment of liver plasma membranes with CHAPS was shown to yield 
glucagon receptor in a soluble, active form. Characterisation of the CHAPS- 
solubilised receptor using sucrose density gradient centrifugation and gel filtration 
on Sepharose CL-6B showed that it exists predominantly in a highly aggregated 
form, and that this aggregation is specific and unchanged by alterations to the 
detergent concentration or ionic strength. The smallest molecular weight species for 
the receptor in CHAPS was determined to be ~ 190 kDa and this is proposed to be a 
trimer of the hormone binding subunit.
Isolation of the active, CHAPS-solubilised receptor was attempted using 
affinity chromatography with immobilised glucagon, prepared by coupling 
bromoacetylated BioGel P-150 to the met-25 residue of glucagon. Specific binding 
of the receptor to the affinity gel was demonstrated. However, various elution 
methods (with glucagon, urea or low pH buffers) did not yield active receptor. 
Attempts to elute the receptor with SDS followed by characterisation on SDS- 
PAGE were unsuccessful due to background non-specific binding to the affinity 
matrix of the majority of proteins present in the CHAPS extract.
Thermostability studies on the CHAPS-solubilised receptor, showing 
biphasic decay at 35°C, provided further evidence of possible receptor 
heterogeneity.
It has been proposed that the desensitisation of adenylate cyclase after 
exposure of hepatocytes to glucagon, or other ligands which stimulate inositol 
phospholipid metabolism, arises as a result of phosphorylation of the glucagon 
receptor by protein kinase C. This was investigated by carrying out isoelectric 
focusing of samples of partially purified (by wheat germ agglutinin-agarose 
chromatography) receptor to which 125I-glucagon had been directly cross-linked by 
UV irradiation, using immobilised pH gradient gels and agarose IEF gels. In both 
cases the procedure was optimised to allow good resolution of the components of
solubilised liver membranes, but focusing of the labelled receptor was not possible, 
presumably due to aggregation and/or precipitation at the site of sample application. 
An alternative approach was to look for a difference in the thermostability of the 
receptor in membrane preparations from control and desensitised hepatocytes. No 
difference was observed, even in the presence of phosphatase inhibitors, indicating 
either that desensitisation is not brought about by receptor phosphorylation, or that 
phosphorylation does occur but does not result in a change in the heat stability of 
the receptor.
Chapter 1 Introduction
1
1.1 Structure of Glucagon
Glucagon, a 29 amino acid polypeptide hormone with a molecular weight of 
3485, has a highly conserved primary structure amongst mammals. The amino acid 
sequence of porcine (Bromer et al., 1957), bovine (Bromer et al., 1971), human 
(Thomsen et al., 1972), rat (Sundby and Markussen, 1971a) and rabbit (Sundby 
and Markussen, 1971b) glucagons is identical (Figure 1.1). However, guinea pig 
glucagon is an exception among mammalian glucagons in that its sequence differs 
by five amino acid residues. Furthermore, duck (Sundby et al., 1972) and turkey 
(Markussen et al., 1972) glucagons differ from porcine glucagon by two and one 
amino acids respectively; however, the crystal forms of both of these avian 
glucagons are identical to that of porcine glucagon despite the difference in primary 
structure. Piscine glucagons appear to differ more substantially with anglerfish 
glucagon showing only 69% homology with porcine glucagon (Trakatellio et al., 
1975).
X-ray crystallography has shown that, in the crystalline state, glucagon 
molecules are self-associated into a-helical trimers. The helical region extends from 
residues 10 to 25 and results in the formation of two hydrophobic regions which 
are buried in the self-association process (Sasaki et al., 1975). In concentrated (>1 
mg/ml) basic solutions, glucagon molecules probably exist as trimers similar to 
those found in the crystal state (Gratzer et al., 1972). A model for the structure of 
glucagon in dilute aqueous solution, i.e. the physiological situation, suggests a 
specific but flexible structure of low free energy with maximised hydrophobic 
close-packing, incorporating p-tums at positions 2-5, 10-13 and 15-18, an a -  
helical region between residues 19-27 and a P-sheet between residues 5-10 (Korn 
and Ottensmeyer, 1983).
Glucagon is a member of a multigenic family of several structurally related 
peptides that includes secretin (Mutt et al., 1970), gastric inhibitory peptide (Brown 
and Dryburgh, 1971), vasoactive intestinal peptide (Mutt and Said, 1974), glicentin
2
His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Ser-
Arg-Arg-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr
Figure 1.1 The Complete Amino Acid Sequence of Porcine 
Glucagon
(Thim and Moody, 1981), peptide HI-27 (Tatemoto and Mutt, 1981) and a growth 
hormone releasing factor (Spiess et al., 1982). However, despite the startling 
similarities in the sequences of these peptides, each one couples to a specific 
receptor protein that will trigger distinct physiological events.
1 .2  Biosynthesis of Glucagon
Glucagon is produced and secreted by the A cells of the islets of 
Langerhans. As with other polypeptide hormones, the synthesis of glucagon 
involves a larger precursor, preproglucagon, which is then enzymatically cleaved to 
give the functional form. Cloning and sequencing of mammalian pancreatic 
glucagon cDNAs from hamster ( Bell et al., 1983), bovine (Lopez et al., 1983) and 
rat (Heinrich et al., 1984) showed that pancreatic preproglucagon is a 180-amino 
acid polypeptide containing the sequences of three glucagon-related peptides in 
tandem, separated by intervening peptides. One of these peptides, glicentin, is a 69- 
amino acid polypeptide which has been isolated from intestine and shown to contain 
the entire sequence of glucagon in residues 33-61 (Thim and Moody, 1981) while
3
residues 1-30 represent the glicentin-related pancreatic peptide (GRPP) isolated 
from porcine pancreas (Thim and Moody, 1982). The two remaining peptides, 
termed glucagon-like peptides (GLPs) I and II, contain 37 and 33 amino acid 
respectively. The gene encoding preproglucagon is also expressed in the L cells of 
the gastrointestinal tract and in the brainstem and hypothalamic neurons, although 
the products of its expression are highly tissue-specific and differ from the 
pancreatic products. It has been shown that transcription of the gene in these tissues 
gives rise to preproglucagon mRNA transcripts which are identical to those 
produced in the pancreas (Mojsov et al., 1986; Drucker and Asa, 1988). Therefore, 
diversification of preproglucagon gene expression leading to the appearance of 
different and highly specific peptides in pancreas, gastrointestinal tract and brain is 
brought about by tissue-specific post-translational modification of a common 
preproglucagon precursor (Mojsov et al., 1986; 0rskov et al., 1987). Proteolytic 
processing takes place as the preproglucagon migrates through the secretory 
pathway from the endoplasmic reticulum via the Golgi apparatus to the secretory 
granules. Figure 1.2 shows a scheme for the processing of preproglucagon in 
pancreas and intestine. The predominant pancreatic products are glucagon, GRPP, 
GLP-I and a large form of GLP-II whereas in the intestine glicentin, 
oxyntomodulin, GLP-I, GLP-II and intervening peptide E-amide predominate.
Transcription of the pancreatic preproglucagon gene has been shown to be 
regulated by a number of factors. Specific cis-acting DNA sequences in the 5'- 
flanking region of the rat glucagon gene direct islet-cell specific glucagon gene 
transcription (Drucker et al., 1987) and it has been shown that one of these 
sequences, the proximal promoter element (Gl), interacts with regulatory DNA 
binding proteins only in A cells, thus restricting glucagon gene expression to these 
cells (Philippe et al., 1988). Transcription of the glucagon gene is negatively 
regulated by insulin (Philippe, 1989), explaining in part the high glucagon levels 
that are observed in states of insulin deficiency such as untreated Type 1 (insulin- 
dependent) diabetes mellitus (Muller et al., 1971). The regulatory action of insulin
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Figure 1.2 Scheme for the processing of proglucagon to specific 
peptides in the pancreas and intestine
is mediated by an insulin-responsive element (IRE) in the 5'-flanking region of the 
gene, probably via interactions with phosphorylated trans-acting factors whose 
phosphorylation state is modified by a cascade of phosphorylation- 
dephosphorylation reactions induced by insulin (Philippe, 1991).
Expression of the glucagon gene is increased by the action of both protein 
kinase C (Philippe e ta l ., 1987; Yamato e ta l., 1990) and cAMP-dependent protein 
kinase A (Knepel et al., 1990; Drucker et al., 1991). This shows the involvement 
of both cAMP and inositol phospholipid pathways in the regulation of transcription 
of the gene. Indeed, the rat glucagon gene has been shown to contain a cAMP 
response element (CRE) in the 5'-flanking region which is proposed to interact with 
a protein kinase A-phosphorylated activating transcription factor (Drucker et al., 
1991).
1 .3  Secretion of Glucagon
It is well established that glucose inhibits the release of glucagon (Ohneda et 
al., 1969) while, conversely, low glucose concentration stimulates its release 
(Gerich et al., 1973). A model has been proposed (Rorsman et al., 1991) whereby 
an increase in glucose concentration leads to stimulation of insulin and GABA 
release from B cells. GABA binds to the GABAA-receptor Cl- channels of A cells 
and increases the Cl" permeability of the A cells. This results in hyperpolarisation, 
inhibition of electrical activity, reduction of Ca2+ influx, decrease in intracellular 
[Ca2+] and suppression of glucagon secretion, as it has been shown that glucagon 
secretion increases with increasing intracellular [Ca2+] (Niki et al., 1986). 
However, as described in section 1.2, insulin itself also has a negative effect on 
glucagon secretion by inhibiting transcription of the glucagon gene. Furthermore, 
somatostatin, another pancreatic hormone which is released in parallel with insulin, 
also inhibits glucagon release.
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The effect of other stimulators or inhibitors of glucagon secretion is highly 
dependent on the concentration of glucose so that substances which would normally 
stimulate the release of glucagon fail to elicit such a response in the hyperglycemic 
state (Unger et al., 1969). Secretion is stimulated by amino acids, with the 
exception of the branch chain amino acids (Rocha et al., 1972). Arginine is a 
particularly potent stimulator and it has been proposed that its effect is mediated by 
protein kinase C-activated increase of glucagon gene expression (Yamato et al., 
1990). Conversely, high concentrations of free fatty acids inhibit glucagon 
secretion (Madison et al., 1968), thus reducing the rate of lipolysis and ketogenesis 
and preventing the development of progressive ketoacidosis during prolonged 
starvation.
Catecholamines stimulate glucagon secretion through both ot2 -adrenoceptors 
(Iguchi et al., 1989) and P2 -adrenoceptors (Lacey et al., 1991). This stimulation 
can be elicited not only by circulating catecholamines but by direct sympathetic 
neural innervation of the pancreas (Iguchi et al., 1989). Cholinergic stimulation also 
increases the secretion of glucagon.
1.4  Physiological and Biochemical Effects of Glucagon
The major target site for glucagon action is the liver and it has been long 
recognised that glucagon is an important regulator of hepatic fuel metabolism. The 
hyperglycemic effect of the hormone is brought about by its activation of 
glycogenolysis and gluconeogenesis in the liver. Glycogenolysis is stimulated by 
glucagon-dependent activation of phosphorylase a and inactivation of glycogen 
synthetase (Unger et al., 1978) while gluconeogenesis is stimulated by a glucagon- 
dependent increase in the expression of the phosphoewo/pyruvate carboxykinase 
gene (Christ et al., 1988) and by increased hepatic uptake of gluconeogenic 
precursors such as alanine and glutamine (Brockman et al., 1975). Additionally,
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glucagon also activates glucose-6-phosphatase, enabling ready conversion of 
glucose-6-phosphate resulting from glycogenolysis and gluconeogenesis to free 
glucose which may then be exported from the liver.
Glucagon inhibits hepatic fatty acid synthesis by decreasing the activity of 
acetyl CoA carboxylase (McGarry et al., 1975). The reduced levels of insulin 
which accompany increased levels of glucagon lead to an increase in delivery to the 
liver of free fatty acids which are directed towards ketogenesis by glucagon- 
stimulated activation of both carnitine palmitoyl transferase I (McGarry et al., 1978) 
and 3-hydroxy-3-methylglutaryl coenzyme A synthase (Quant et al., 1987).
Additional effects of glucagon on the liver include stimulation of urea 
synthesis (Petersen et al., 1987), reduction of steroid metabolism (Hussin et al.,
1988) and stimulation of tyrosine aminotransferase during embryonic development 
(Onoagbe and Dickson, 1992).
In addition to the liver, glucagon has been shown to exert important 
physiological effects on other tissues. These include lipolysis in adipose tissue 
(Hagen, 1961), stimulation of renal bicarbonate excretion (Paillard and Bichara,
1989), inhibition of gastric acid secretion (Bataille et al., 1988), stimulation of 
insulin secretion by pancreatic B cells (Freychet, 1990) and regulation of branch- 
chain amino acid metabolism in the heart (Hildebrandt et al., 1988).
It has long been known that the physiological effects of glucagon are 
brought about by the elevation of intracellular cAMP concentration. However, more 
recently it has been shown that glucagon can activate cAMP-independent processes 
through the stimulation of phospholipid metabolism. This is discussed in detail in 
section 1.6.4.
1.5 Glucagon and Diabetes
Hyperglucagonemia is a common characteristic of both Type 1 (insulin- 
dependent) and Type 2 (non-insulin-dependent) diabetes mellitus. The presence of 
this state in untreated Type 1 diabetics is caused in part by a lack of an inhibitory 
effect of insulin on glucagon biosynthesis and secretion. However, the 
development of hyperglycemia in both Type 1 and Type 2 diabetes would be 
expected to inhibit glucagon secretion (section 1.3), but this is often not the case, 
suggesting insensitivity of A cells to glucose in the diabetic state (Freychet, 1990). 
It has been shown that hepatic response to glucagon is decreased in both Type 1 
(0rskov et al., 1991) and Type 2 (Amer et al., 1987) diabetes mellitus, resulting in 
decreased hepatic glucose production, and it is suggested that this is possibly a 
mechanism for reducing the effect of hyperglycemia.
1 .6  Glucagon Receptor
1 .6 .1  Cellular and Subcellular Distribution of Glucagon
Receptors
Specific glucagon-binding sites have been described in a number of 
mammalian and avian tissues, including liver (Rodbell et a l . , 1971), adipose tissue 
(Desbuquois et al., 1973), heart (Klein et al., 1973), pancreas (Goldfine et al., 
1972), brain (Hoosein and Gurd, 1984) and retina (Sanchez et al., 1988). Studies 
with separate liver cell populations have shown that only hepatocytes (parenchymal 
cells) contain glucagon binding sites (Wincek etal., 1975).
In hepatocytes, specific glucagon binding sites are predominantly associated 
with plasma membranes although minor amounts have been identified in 
endoplasmic reticulum and Golgi membranes (Desbuquois, 1983).
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1 .6 .2  G lucagon-Receptor Binding
The binding of glucagon to hepatic plasma membranes and isolated 
hepatocytes does not conform to a single binding equilibrium. As much as a 
50,000-fold increase in the concentration of hormone is required to cause a 
reduction from 90% to 10% of maximal binding of 1 2 5 I-labelled glucagon whereas 
theory predicts that a 1 0 0 -fold increase should be sufficient for a single binding 
equilibrium (Mason and Tager, 1985). This complex binding has been modelled in 
terms of a time-dependent, temperature-dependent, non-cooperative interconversion 
of two states of a single receptor population (Horwitz et al., 1985). In this model, 
binding of glucagon to the receptor yields a low affinity complex which converts 
with time to a high affinity complex, the conversion step being independent of the 
degree of fractional receptor occupancy and occurring at 37°C but not at 0°C. The 
presence of low and high affinity states and their differing dissociation rates account 
for the kinetic complexity of binding. Horwitz et al. (1986) proposed that the 
conversion from low to high affinity complexes is required for stimulation of 
adenylate cyclase, either through direct activation by the high affinity complex 
coupling to the stimulatory guanine nucleotide binding protein or by energetic 
coupling of the conversion process with adenylate cyclase activation.
Alternatively, the observed complexity of glucagon-receptor interactions has 
been modelled in terms of two non-interacting populations of receptor, one with a 
high affinity and the other with a low affinity for glucagon (Bonnevie-Nielsen and 
Tager, 1983; Mason and Tager, 1985), and it has been proposed that occupancy of 
the high affinity sites is required to elicit a biological response (Hagopian et al.,
1987). This model was modified further by Bharucha and Tager (1990) to account 
for the demonstration of the conversion of reversibly bound glucagon to a 
nondissociable state in which glucagon remains irreversibly bound even after acid 
or protease treatment. Hence, four glucagon-receptor complexes were proposed to 
account for dissociable and non-dissociable interactions with both high and low
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affinity binding sites. The ratio of high to low affinity sites was shown to be 
approximately 1 :1 0 .
1 . 6 . 2 . 1  Effect of Guanine Nucleotides on Binding
Guanine nucleotides decrease the affinity of glucagon for its receptor in liver 
membranes (Rodbell et al., 1971). The effect of GTP on receptor binding affinity 
arises as a result of binding of GTP to the stimulatory G protein. High affinity 
binding of glucagon to its receptor is proposed to arise from binding to a receptor 
associated with a stimulatory G protein. Binding of GTP to the G protein results in 
its dissociation from the receptor and the subsequent conformational change in the 
receptor results in low affinity binding of glucagon.
Wyborski et al. (1988) have proposed that the effect is due to guanine 
nucleotides slowing the conversion of the receptor from a low affinity to high 
affinity state by stabilising the low affinity conformation. The rank order among 
naturally occurring guanine nucleotides for stabilising the low affinity state is GTP 
> GDP »  GMP = no nucleotides. Hence it was proposed that while GTP is 
required for coupling of the glucagon receptor to adenylate cyclase, it also regulates 
activation of adenylate cyclase by slowing the conversion of "inactive" low affinity 
glucagon-receptor complexes to "active" high affinity complexes.
Binding of GTP to a cytoplasmic site on the glucagon receptor has also been 
proposed (Iyengar et al., 1979; McVittie and Gurd, 1989).
1 .6 .2 . 2  Effect of Ions on Binding
A number of salts inhibit the binding of glucagon to its receptors in liver 
membranes (Desbuquois, 1983). With monovalent ions, inhibition is demonstrable 
at 0.1 M and is virtually complete at 1 M. Divalent cations decrease glucagon 
binding at lower concentrations. However, in the presence of GTP, maximal
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binding occurs in the presence of 2.5 mM Mg2+, suggesting a role for this cation in 
the regulation of glucagon receptor affinity and the presence of a cation binding site 
on the receptor (Lipson et al., 1988) or the stimulatory G protein (Bimbaumer et 
al., 1990).
1 . 6 . 3  Glucagon Receptor Structure
In the absence of a successful procedure for the purification of the glucagon 
receptor, much of the known information on its size and structure has been obtained 
from the techniques of target size analysis and photoaffinity cross-linking. Early 
work using target size analysis by irradiation inactivation gave conflicting 
information about the size and association state of the glucagon receptor in the 
membrane environment. Houslay et al. (1977) proposed an independent, mobile 
receptor of 217 kDa, although this work did not include analysis of the possible 
contribution of regulatory guanine nucleotide binding proteins. Martin et al. (1979) 
proposed that in the absence of glucagon the receptor exists in a free form but that 
binding of glucagon to receptor results in the association of the receptor with G 
protein and adenylate cyclase in a transient complex which is dissociated by GTP. 
The existence of the receptor in the membrane in the form of large (670 kDa) 
multimeric complexes associated with G proteins was proposed by Schlegel et al. 
(1979).
Covalent cross-linking of labelled hormone to its receptor has been an 
important method in the identification and characterisation of peptide hormone 
receptors, e.g. the insulin receptor (Pilch and Czech, 1980) and indeed has been 
used to identify the glucagon receptor. Cross-linking has been demonstrated using 
heterobifunctional cross-linking reagents such as 2-nitro-4-azidophenylsulphenyl 
chloride (NAPSC1) (Demoliou and Epand, 1980; Demoliou-Mason and Epand, 
1982) and hydroxysuccinimidyl-/?-azidobenzoate (HSAB) (Johnson etal., 1981;
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Iyengar and Herberg, 1984; Herberg et al., 1984). The use of NAPSC1 involves 
the synthesis of a photoreactive radiolabelled glucagon (1 2 5 I-glucagon-NAPS) 
which is incubated with liver plasma membranes. UV irradiation is then used to 
form a covalent cross-link between the glucagon derivative and the receptor. 
However, using HSAB no glucagon derivative is synthesised; instead, 
radiolabelled glucagon is incubated with membranes, HSAB is added and UV 
irradiation is carried out. Direct cross-linking by UV irradiation, without the use of 
photoaffinity reagents, was later reported (Iwanij and Hur, 1985).
The method of photoaffinity cross-linking has resulted in conflicting 
information about the molecular structure of the glucagon receptor. Johnson et al.
(1981), using HSAB for cross-linking, identified an 1 2 5 I-labelled glucagon binding 
rat liver plasma membrane protein of 53 kDa. Later, Demoliou-Mason and Epand
(1982), using 1 2 5 I-glucagon-NAPS for cross-linking, reported a receptor complex 
of 200-250 kDa from Ultrogel chromatography of photolabelled Lubrol-solubilised 
membranes and, on the basis of results from gel electrophoresis of those fractions 
containing the complex, proposed that the glucagon receptor in Lubrol-PX is an 
oligomer composed of at least two subunits in the molecular weight range 52-70 
kDa that are linked together or greatly stabilised by disulphide bonds.
Iyengar and Herberg (1984) reported the labelling of a 63 kDa peptide by 
1 2 5 I-glucagon using HSAB as cross-linker. This labelling was inhibited by low 
concentrations of unlabelled glucagon but unaffected by other peptide hormones, 
indicating that it was specific for glucagon. Labelling was also shown to be 
sensitive to GTP, indicating that the 63 kDa peptide had the capacity to interact with 
the stimulatory guanine nucleotide binding protein. The localisation of the hormone- 
binding region within this 63 kDa peptide was studied by comparing the effect of 
limited elastase treatment of membranes that had 1 2 5 I-glucagon specifically but not 
covalently bound to treatment of membranes prior to exposure to the labelled 
hormone. Bound label was then cross-linked and the membranes analysed by SDS- 
PAGE. It was shown that elastase treatment of the unoccupied receptor yielded a 24
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kDa peptide that bound 1 2 5 I-glucagon specifically. Labelling of this peptide was 
sensitive to GTP, indicating that the fragment retained the capacity to interact with 
the stimulatory guanine nucleotide binding protein. However, treatment of the 
hormone occupied receptor with elastase resulted in the identification of a 33 kDa 
peptide which, like the 24 kDa peptide, was shown to retain the capacity to interact 
with the stimulatory guanine nucleotide binding protein. The 33 kDa protein was 
also given by the action of other proteases such as subtilisin, protease V8  and 
trypsin, and is in fact the most commonly observed naturally occurring fragment of 
the receptor when the hormone-binding reaction is carried out in the absence of 
protease inhibitors. Elastase treatment of the 33 kDa peptide resulted in the 
formation the 24 kDa peptide and a 15 kDa peptide, indicating that the 24 kDa 
peptide is contained within the 33 kDa peptide.
Treatment of the labelled 63 kDa peptide with endo-p-N -acetyl- 
glucosaminidase F (Endo F) resulted in the appearance of four discrete bands on 
SDS-PAGE gels, suggesting the presence of at least four N-linked glycans and a 
peptide 'backbone' of 45 kDa. However, treatment of the 24 kDa and 33 kDa 
peptides with Endo F indicated that neither of these fragments contain N-linked 
glycans.
Iyengar and Herberg concluded that the glucagon receptor is a glycoprotein 
of -60 kDa which contains at least four N-linked glycans accounting for 18 kDa, 
with the hormone-binding function and capacity to interact with the stimulatory 
regulator contained within a fragment of -21 kDa. They proposed that hormone 
occupancy of the receptor results in the exposure of a proteolytically sensitive 
region which can be acted upon by proteases to form a peptide of -30 kDa which 
does not contain any N-linked glycans but still contains the hormone-binding and 
stimulatory regulator-interacting regions. Since deglycosylated membrane proteins 
turn over more rapidly than their glycosylated counterparts (Olden et al., 1982), it 
was proposed that the formation of the 33 kDa peptide plays a role in the down- 
regulation of the receptor.
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Herberg et al. (1984) later reported the identification of a 119 kDa species 
after solubilisation of cross-linked membranes with Lubrol-PX and proposed that 
the hepatic glucagon receptor exists in the membrane and in non-denaturing 
detergent solution as a dimer of the 60 kDa hormone-binding subunit.
Direct cross-linking by UV irradiation, without the use of any cross-linking 
reagents, was used by Iwanij and Hur (1985) to identify a glucagon-receptor 
complex of 62 kDa and they proposed the presence of intramolecular disulphide 
bonds since reduction of the complex with dithiothreitol resulted in a decrease in the 
electrophoretic mobility. The presence of four N-linked glycans on the receptor was 
again demonstrated.
Proteolytic mapping studies using monoclonal antibodies prepared against 
partially purified directly cross-linked rat hepatic glucagon receptor (Iwanij and 
Vincent, 1990) have shown that the hormone binding site of the receptor is located 
on a 25 kDa fragment containing the intact COOH-terminal domain and the structure 
of the receptor has been proposed to be similar to the structure of the rhodopsin 
molecule, as has been shown for other receptors which transduce signals via 
guanine nucleotide binding proteins, including muscarinic acetylcholine receptors 
(Peralta et al., 1987) and adrenergic receptors (O' Dowd et al., 1987). This 
structure consists of seven transmembrane domains with three extracellular and 
three cytoplasmic loops. The extracellular amino terminal domain usually contains 
one or more sites for N-linked glycosylation, while the cytoplasmic domains often 
contain potential sites for phosphorylation by one or more cytosolic kinases. Not all 
receptors which interact with G proteins have this structure, e.g the receptor for 
insulin-like growth factor II has a single membrane-spanning domain (Okamoto et 
al., 1990). However, the predicted amino acid sequence obtained from the recent 
isolation of a cDNA clone for the glucagon receptor (Jelinek et al., 1993; Svoboda 
et al., 1993) has suggested that the seven transmembrane domain model is indeed 
applicable to the glucagon receptor (see section 5.3).
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Species specific structural differences among glucagon receptors have been 
suggested by the failure of antibodies raised against the rat receptor to recognise the 
chicken or canine forms of the receptor (Iwanij and Vincent, 1990).
1 . 6 . 4  Glucagon Receptor and Signal Transduction
It is well established that treatment of hepatocytes with glucagon causes an 
elevation of the intracellular concentration of cyclic AMP. This process involves the 
binding of glucagon to its receptor followed by a conformational change which 
results in coupling of the receptor to the stimulatory G protein, Gs. This causes the 
a  subunit of Gs to exchange a bound GDP for GTP and to dissociate from the py 
subunits. The GTP-bound form of the a  subunit then activates the catalytic subunit 
of adenylate cyclase, resulting in the production of cAMP. The increase in 
intracellular cAMP is rapid but transient due to its degradation by specific 
phosphodiesterases, at least one of which is activated by protein kinase A-activated 
phosphorylation (Kilgour et al., 1989), and the desensitisation of glucagon- 
stimulated adenylate cyclase (see section 1.7). Glucagon has also been shown to 
exert cAMP-independent actions on hepatocytes. Early evidence showed that low 
concentrations of glucagon could exert metabolic effects while giving no discernible 
increase in either cAMP concentration or protein kinase A activity (Bimbaum and 
Fain, 1977; Okajima and Ui, 1976). Later work showed that the glucagon 
analogues TH-glucagon and TNP-glucagon were unable to activate adenylate 
cyclase or increase the intracellular concentration of cAMP yet brought about the 
full stimulation of glycogenolysis, gluconeogenesis and urea synthesis in 
hepatocytes (Corvera et al., 1984; Cote and Epand, 1979). These results suggest 
the involvement of glucagon in the activation of other signal transduction 
pathway(s) in addition to stimulation of adenylate cyclase. Both glucagon and TH- 
glucagon have been shown to stimulate inositol phospholipid metabolism (Wakelam
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et al., 1986; Blackmore and Exton, 1986; Whipps et al., 1987) and indeed 
glucagon can increase the intracellular concentrations of both diacylglycerol 
(Bocckino et al., 1985) and free Ca2+ (Blackmore and Exton, 1986; Mine et al., 
1988), both of which could result from stimulation of inositol phospholipid 
metabolism, although the increase in free Ca2+ concentration is proposed to be a 
result of both cAMP-dependent and cAMP-independent processes (Mine et al.,
1988). It is also possible that diacylglycerol production can come from the 
breakdown of phosphatidylcholine (Muir and Murray, 1987). The involvement of 
glucagon in two different signal transduction pathways has led to the proposal of 
there being two different glucagon receptors, one coupled to adenylate cyclase and 
the other coupled to (inositol) phospholipid metabolism (see section 1 .6 .6 .2 ).
1 .6 .5  Receptor Solubilisation and Activity
The choice of detergent for the solubilisation of native membrane proteins is 
often critical. Conformational denaturation of a protein upon solubilisation may 
arise as a result of changes in the environmental fluidity upon incorporation of the 
protein into micelles (Milder et al., 1991), binding of detergent to the protein at sites 
not normally occupied by lipid (Simmonds et al., 1982) or displacement from the 
protein surface of lipids needed to stabilise the protein structure (Robinson et al., 
1980). In addition, loss of activity can result from detergent-induced dissociation of 
cofactors or associated proteins, as well as specific interference by the detergent in 
the binding of substrates or ligands to the protein (Hjelmeland, 1990).
Both ionic and non-ionic detergents have been successfully used in the 
solubilisation and subsequent purification of membrane proteins. However, there 
appears to be no wholly rational basis for the selection of a particular detergent or 
class of detergents for a given application. In some cases homologous membrane 
proteins can be successfully solubilised using similar conditions, e.g. solubilisation
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of the p2 -adrenergic receptor and its homologues with digitonin (Schorr et al., 
1981; Niznik et al., 1986; Regan et al., 1986) whereas in other cases preparations 
of the same protein from different sources can show different patterns of stability in 
the same detergent, e.g. (Na+ + K+) - ATPases in C^Eg (Esmann, 1986).
The glucagon receptor behaves as a typical integral membrane protein in that 
treatment of labelled liver plasma membranes with lithium diiodosalicylate does not 
result in extraction of the cross-linked receptor (Iwanij and Hur, 1985) whereas it is 
solubilised by treatment with detergents such as Lubrol-PX (Demoliou-Mason and 
Epand, 1982; Herberg etal., 1984; Iwanij and Vincent, 1990) and digitonin (Iwanij 
and Hur, 1985). However, detergent treatment of unlabelled membranes 
predominantly yields solubilised glucagon receptors that do not retain hormone- 
binding activity. Herberg et al. (1984) showed that while some activity is retained 
after extraction with deoxycholate, cholate and octylglucoside, the most effective 
detergent for solubilisation of active glucagon receptor is CHAPS. However, 
CHAPS-solubilised receptor is unstable, showing an almost total loss of activity 
after just 8  hours at 4°C. The presence of 137 mM NaCl in the extraction solution 
increases the stability of the receptor so that 50% of binding activity remains after 
24 hours, but traditional stabilising agents such as glycerol, sucrose, dithiothreitol 
and supplemental phospholipid are ineffective in stabilising the soluble receptor 
(McVittie and Gurd, 1989).
The CHAPS-solubilised glucagon receptor was shown by competition 
binding assays to bind hormone with low affinity in a guanine nucleotide- 
insensitive manner (Herberg et al., 1984). McVittie and Gurd (1989) used 
dissociation assays to show that the solubilised receptor is capable of 
interconversion from the low affinity to the high affinity state in a guanine 
nucleotide-sensitive manner as observed for the membrane-bound receptor, GTP 
favouring the low affinity form and requiring the presence of Mg2+ for its effect to 
be seen.
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1 . 6 . 6 Heterogeneity of the Glucagon Receptor
Evidence of glucagon receptors with different affinity to the hormone and 
different glycosylation, and the observation that glucagonjactivates two separate 
signalling pathways, has led to proposals that there is a heterogeneous population 
of glucagon receptors in liver.
1 . 6 .6 . 1  Differential Receptor Affinity and Glycosylation
As described in section 1.6.2, the complex binding of glucagon to its 
receptor has been modelled both in terms of a single population of receptors which 
interconvert between low and high affinity forms, and two non-interacting receptor 
populations of high and low affinity. A correlation between affinity and 
glycosylation has been made by Mason and Tager (1985). They used gel filtration 
and affinity chromatography of digitonin-solubilised non-cross-linked glucagon- 
receptor complexes from canine hepatic plasma membranes to identify two forms of 
the receptor, one of which was found to bind to wheat germ agglutinin and was 
specifically eluted by N-acetylglucosamine and the other of which was found not to 
bind. Analysis of material from membranes incubated with 1 2 5 I-glucagon and with 
different concentrations of unlabelled glucagon showed that low concentrations of 
the competitor caused radioactivity in the fraction specifically bound to wheat germ 
agglutinin to decrease markedly whereas higher concentrations of competitor were 
required to decrease radioactivity in the unbound fraction. Indeed, the values for 
concentrations of unlabelled glucagon required to give half-maximal inhibition of 
1 2 5 I-glucagon association with receptor agreed well with the dissociation constants 
derived mathematically from the overall interaction of glucagon with soluble 
receptors. Thus it was shown that high affinity receptors bind to wheat germ 
agglutinin whereas low affinity receptors do not bind to the agglutinin and hence it 
was proposed that separate populations of glucagon receptors with different
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affinities for hormone arise as a result of differential glycosylation. However, 
wheat germ agglutinin chromatography of Lubrol-solubilised cross-linked 
glucagon-receptor complexes has yielded conflicting results. Herberg et al. (1984) 
found no labelled receptor remaining in solution after exposure to wheat germ 
agglutinin-Sepharose, whereas Iwanij and Vincent (1990) found that the 
flowthrough contained labelled material of a slightly lower molecular weight than 
that of the adsorbed receptor, and proposed that this represented a desialiated form 
of the receptor.
1 . 6 .6 . 2  Signal Transduction Pathways and Receptor 
Heterogeneity
As described previously (section 1.6.4) glucagon can exert effects through 
the stimulation of both adenylate cyclase and inositol phospholipid metabolism. 
Therefore it has been proposed that glucagon exerts its effect on liver via two 
different receptors rather than via a single receptor coupled to two signalling 
pathways (Wakelam et al., 1986). This hypothesis was supported by the 
observation that the Ka value for the action of glucagon in stimulating the inositol 
phospholipid response is lower than that for its ability to stimulate adenylate 
cyclase. Hence it was proposed that rat hepatocytes have two functionally distinct 
receptors with different affinities: GR1 receptors coupled to the stimulation of 
inositol phospholipid metabolism, and GR2 receptors coupled to the stimulation of 
adenylate cyclase.
Other receptor systems show that coupling to adenylate cyclase and 
phospholipid metabolism can occur through single or multiple receptor populations. 
For example, the effects of vasopressin are mediated through three different 
receptors (Bimbaumer et al., 1990). V-la receptors are coupled to stimulation of 
phospholipases C, D and A2  and the inhibition of adenylate cyclase. V-lb receptors 
are coupled to the stimulation of phospholipase C, while V-2 receptors stimulate
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adenylate cyclase. These effects are suggested to be mediated by the coupling of 
different receptors to different G proteins. Conversely, calcitonin stimulates both 
inositol phospholipid metabolism and adenylate cyclase via a single receptor 
(Chabre et al., 1992). In this case, stimulation of two different signalling pathways 
is proposed to be brought about by the coupling of two different G proteins to a 
single receptor population.
1 .7  Desensitisation of Glucagon-Stimulated Adenylate
Cyclase
Glucagon treatment of intact hepatocytes causes a rapid time- and dose- 
dependent desensitisation of glucagon-stimulated adenylate cyclase activity 
(Murphy et al., 1987). The total number of glucagon binding sites is unaltered over 
the period of desensitisation, indicating that internalisation of receptor does not 
occur during this period of time. TH-glucagon which, as mentioned previously, 
does not cause an increase in cAMP, also brings about desensitisation, 
demonstrating that the desensitisation of glucagon-stimulated adenylate cyclase is a 
cAMP-independent process. Since both glucagon and TH-glucagon have been 
shown to stimulate inositol phospholipid metabolism (Wakelam et al., 1986), it has 
been proposed that glucagon brings about the desensitisation of the ability of GR-2 
receptors to stimulate adenylate cyclase by stimulating inositol phospholipid 
metabolism through GR-1 receptors. This is supported by the observation that other 
ligands known to stimulate inositol phospholipid metabolism in hepatocytes such as 
angiotensin and vasopressin also elicit desensitisation of glucagon-stimulated 
adenylate cyclase. Since the phorbol ester TPA, a known stimulator of protein 
kinase C, mimicks this desensitisation, it is proposed that the stimulation of protein 
kinase C plays an important role in the molecular mechanism of desensitisation of 
glucagon-stimulated adenylate cyclase. Indeed, diacylglycerol, a product of inositol
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phospholipid metabolism, is a stimulator of protein kinase C and treatment of 
hepatocytes with two synthetic diacylglycerols has been shown to mimic glucagon- 
mediated desensitisation of adenylate cyclase (Newlands and Houslay, 1991). The 
molecular mechanism of desensitisation is not due to the activation of the inhibitory 
guanine nucleotide regulatory protein G* as this protein has been shown to be 
inactivated upon treatment of hepatocytes with glucagon (Murphy et al., 1989). 
Hence it is proposed that desensitisation occurs as a result of phosphorylation of 
either the glucagon receptor or the stimulatory G protein followed by the 
uncoupling of the ability of these two proteins to interact (Murphy et al., 1987). As 
treatment of isolated membranes with pure protein kinase C does not result in the 
phosphorylation of the stimulatory G protein (Bushfield et al., 1990), 
phosphorylation of the glucagon receptor seems more likely.
Receptor phosphorylation and subsequent impairment of receptor-Gs 
coupling has been shown to play an important role in the desensitisation of 
adenylate cyclase in p2 -adrenergic receptor systems. This receptor is a target for 
three different kinases: protein kinase A (Benovic et al., 1985; Bouvier et al., 
1987), p2 -adrenergic receptor kinase (Benovic et al., 1987) and protein kinase C 
(Johnson et al., 1990). However, a difference between the ability of the three 
kinases to phosphorylate the p2 -adrenergic receptor is that whilst the presence of 
agonist is essential for the action of p2 -adrenergic receptor kinase and enhances the 
rate of phosphorylation of the receptor by protein kinase A, there appears to be no 
requirement for agonist to be present for the action of protein kinase C. 
Phosphorylation by both protein kinase A and P2 -adrenergic receptor kinase has 
been shown to lead directly or indirectly to uncoupling of the receptor from Gs 
(Kobilka, 1992) and it is proposed that phosphorylation by protein kinase C brings 
about a similar action. Indeed, the treatment of cells with phorbol esters to activate 
protein kinase C has been shown to lead to the uncoupling of Gs from the receptor 
(Garte and Belman, 1980).
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1.8 Aims Of Project
The elucidation of the mechanism of action of glucagon stimulation of 
adenylate cyclase and inositol phospholipid metabolism at the molecular level 
requires a detailed understanding of the structure and function of the glucagon 
receptor. Some information on the structure of the receptor has been obtained by the 
use of affinity cross-linking techniques and some progress has been made in the 
solubilisation and stabilisation of free, active receptor, an important initial step in its 
isolation. However, to date the receptor has not been purified to homogeneity. 
Therefore, full characterisation of its structure, including the possibility of there 
being two or more structurally distinct forms, and its role in the transduction of 
binding signal to intracellular action has not been achieved. The aims of this project 
were the isolation and further characterisation of the rat hepatic glucagon receptor, 
especially with regard to receptor heterogeneity and the possibility of receptor 
phosphorylation in the desensitisation of glucagon-stimulated adenylate cyclase. 
Two lines of investigation were undertaken:
i) studies on the CHAPS-solubilised receptor, including stabilisation, 
characterisation and attempted isolation using affinity chromatography on 
immobilised glucagon
ii) use of affinity cross-linking and thermostability studies to investigate the 
possibility of receptor phosphorylation.
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Chapter 2 Materials and Methods
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2.1 Materials
2 . 1 . 1  Fine Chemicals
A-acetylglucosamine (GlcNAc), bovine serum albumin, Coomassie blue G and R, 
dextran, glucagon, hydrogen peroxide, leupeptin, Lubrol-PX, NADH, Nonidet 
P40, ovalbumin, oxaloacetic acid, pepstatin A, phenylmethylsulphonyl fluoride 
(PMSF), o-phospho-L-serine and N ,A ,N ',N '-tetram ethylethylenediam ine 
(TEMED) were obtained from Sigma Chemical Company, Poole, Dorset, U.K.
Acrylamide, EDTA, Folin & Ciocalteau's reagent, A-2-hydroxyethylpiperazine-A'- 
2-ethanesulphonic acid (HEPES), AW'-methylenebisacrylamide and sodium 
dodecyl sulphate (SDS) were supplied by FSA Laboratory Supplies, 
Loughborough, U.K.
Ammonium persulphate, bromophenol blue, citric acid, formaldehyde, 2- 
mercaptoethanol and sodium deoxycholate were obtained from BDH Chemicals 
Ltd., Poole, U.K.
Aprotinin and 3-[(cholamidopropyl)dimethylammonio]-l-propansulphonate 
(CHAPS) were obtained from Boehringer Mannheim, East Sussex, U.K.
Norit A activated charcoal was supplied by Aldrich Chemical Company Ltd., 
Gillingham, Dorset, U.K.
Ampholine, pH 3.5-10 was obtained from Pharmacia LKB Biotechnology, 
Uppsala, Sweden.
Okadaic acid was supplied by Calbiochem, Nottingham, U.K.
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onitrophenyl-/I-D-galactopyranoside was obtained from Koch-Light Laboratories 
Ltd., Colnbrook, Bucks., U.K.
All other chemicals used were of the highest grade available. All solutions were 
prepared, where appropriate, with deionised distilled water (dH2 0 ).
2 . 1 . 2  Radiochemicals
Iodine-125 (supplied as sodium iodide in dilute sodium hydroxide solution, pH 7- 
11, 15.2 Ci 1 2 5 I/|ig iodine) and (3-[1 2 5 I]-iodotyrosyl10) glucagon (~2000Ci/mmol) 
were obtained from Amersham International pic, Amersham, U.K
2 . 1 . 3  Enzymes
Catalase (18600 units/mg), /3-galactosidase (315 units/mg) and malate 
dehydrogenase (2600 units/mg) were obtained from Sigma Chemical Company, 
Poole, Dorset, U.K.
2 . 1 .4  Chromatographic and Electrophoretic Materials
Immobiline DryPlates (pH 4-7), GelBond film for agarose gels, agarose IEF, 
Sepharose CL-6 B and gel filtration calibration standards were supplied by 
Pharmacia-LKB Biotechnology, Uppsala, Sweden.
Bio-Gel P-150 was obtained from Bio-Rad, Hemel Hempstead, Herts., U.K.
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Wheat germ agglutinin-agarose (WGA-agarose) was obtained from Vector 
Laboratories, Peterborough, U.K.
"Rainbow markers", molecular weight range 14 300-200 000, for SDS-PAGE 
were obtained from Amersham International pic, Amersham, U.K.
2 . 1 . 5  Other Materials
Cellulose acetate filters (0.45|im pore size) were obtained from Schleicher & 
Schuell, Dassel, Germany. Centricon-10 microconcentrators were obtained from 
Amicon Ltd., Stonehouse, Glos., U.K.
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2.2  Methods
2 . 2 . 1  Purification of Plasma Membranes from Whole Rat Liver
Liver plasma membranes were prepared using a modification (Marchmont et 
al., 1981) of the method of Pilkis et al. (1974).
Three fed male Sprague-Dawley rats (-250 g) were stunned and decapitated 
and their livers were removed, washed and chopped in ice-cold 1 mM KHCO3 , pH 
7.2. Using three volumes of liver : one volume of KHCO3  solution, the livers were 
homogenised in a 50ml glass Potter-Elvejm homogeniser with six strokes of a 
motor-driven Teflon pestle. The homogenate was strained through two layers of 
muslin, diluted to 250 ml with KHCO3  solution and centrifuged at 2 000 g for 10 
minutes at 4°C. The resultant supernatant was discarded and the pellets poured onto 
sucrose (72 g) in a plastic beaker. The volume was made up to 120 ml with 
KHCO3  solution and this suspension was stirred for 30 minutes at 4°C. Portions of 
2 0  ml were then pipetted into clear centrifuge tubes and on top of each portion was 
carefully layered 48.2% (w/v) sucrose in 3 mM imidazole, pH 7.4 (12 ml), 
followed by 42.5% (w/v) sucrose in 3 mM imidazole, pH 7.4 (6.5 ml). These 
gradients were centrifuged at 100 000 g for 3 hours in a Beckman ultracentrifuge 
using an SW 28 rotor at 4°C. The plasma membranes collected as a fluffy brown 
band at the 42.5-48.2% sucrose interface were aspirated using a pasteur pipette, 
diluted with an equal volume of KHCO3  solution and centrifuged at 25 000 g for 15 
minutes at 4°C. The resultant pellet was resuspended in KHCO3  solution ( 6  ml) and 
stored at -80°C in 0.5 ml aliquots (3-4 mg protein/ml).
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2 .2 .2  Purification of Plasma M em branes from  Isolated Rat 
H epatocytes
Isolated hepatocytes from fed male Sprague-Dawley rats (-250 g) were 
prepared by Dr. A. Savage using the method of Berry and Friend (1969). The 
following protocol describes the preparation of plasma membranes from 
hepatocytes obtained from one liver.
Cells were suspended in 1 mM KHCO3 , pH 7.2 (20 ml) and homogenised 
in a 50 ml glass Potter-Elvejm homogeniser with six strokes of a motor-driven 
Teflon pestle. The homogenate was diluted to 40 ml with KHCO3  solution and 
spun at 2 000 g for 10 minutes at 4°C. The resultant supernatant was discarded and 
the pellet poured onto sucrose (24 g). The volume was made up to 40 ml with 
KHCO3  solution and the suspension was stirred for 30 minutes at 4#C. Purification 
of the plasma membranes on sucrose density gradients was then carried out as 
described in section 2.2.1, the final pellet being resuspended in KHCO3  solution ( 1  
ml) and stored at -80°C in 0.2 ml aliquots.
2 .2 .3  Estim ation of Protein Concentration
Protein concentration was estimated using the method of Lowry et al. (1951) or 
Bradford (1976), using 1 mg/ml bovine serum albumin as the standard protein 
solution in each case.
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2 .2 .4 Iodination of Glucagon
When possible, commercially obtained (3-[1 2 5 I]-iodotyrosyl10) glucagon 
was used. However, due to the cost of this radiochemical it was occasionally 
necessary to prepare iodinated glucagon using a modification of the method of 
Giorgio et al. (1974).
Glucagon (5 p.1 of a 1 mM solution in 0.5M Tris-HCl, pH 8.5) was placed 
at the bottom of a plastic micro tube. On the sides of the tube was placed 6  mM 
chloramine T in 0.6 M phosphate buffer, pH 7.4 (5 p.1) and Na125I solution (20 jxl, 
~2mCi). The reaction was initiated by mixing and allowed to proceed for 10-15 
seconds. Termination was achieved by the addition of 3mM sodium metabisulphite 
in 0.6 M phosphate buffer, pH 7.4 (50 |il). The reaction mixture was transferred to 
a 15 ml conical centrifuge tube with 1% (w/v) BSA in lOmM Tris-HCl, pH 7.6 ( 8  
ml) and after the addition of talc (50 mg) the contents were mixed and cenrifuged at 
1 000 g for 20 minutes at 25°C. The pellet was washed four times with 0 . 1  M 
phosphate buffer, pH 7.0 ( 8  ml), discarding the washings. Following extraction of 
purified 1 2 5 I-glucagon from the talc with 50% (v/v) aqueous ethanol ( 6  ml) and 
removal of the solvent by evaporation under reduced pressure, the residue was 
extracted with 0.1% (w/v) ovalbumin in Tris-HCl, pH 7.6 (2 ml) and stored at - 
20°C in 0.2 ml aliquots. Under these storage conditions radiation destruction of the 
glucagon occurred so that after 3-4 weeks reprocessing through the talc procedure 
was necessary.
2 .2 .5  Binding of 1 2 5 I-gIucagon to Liver Plasm a M em branes
Rat liver plasma membranes were incubated at a final concentration of 50- 
100 fig protein/ml in a final reaction volume of 100 fil containing 0.1% (w/v) BSA, 
1 mM EDTA, 20 mM Tris-HCl, pH 7.5 (Buffer A), 0.1-0.2 nM 1 2 5 I-glucagon
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and, when measuring non-specific binding, 1 pM unlabelled glucagon. Incubation 
was carried out for 20 minutes at 32°C. The reaction was then stopped by the 
addition of ice-cold Buffer A (5 ml) to the tubes and the diluted samples were 
immediately filtered through 0.45-pm cellulose acetate filters which had been 
soaked in 10% BSA overnight and washed with ice-cold Buffer A (2 ml). The 
tubes were rinsed once with ice-cold Buffer A (5 ml) and the rinses filtered. The 
filters were then washed with a final 5 ml portion of ice-cold Buffer A and the 
radioactivity bound to them was measured using a y counter. Non-specific binding, 
measured in the presence of 1 pM unlabelled glucagon, was typically 5-10% of the 
total binding.
2 . 2 . 6  Direct Cross-linking of 125I-glucagon to Liver Plasma
Membranes by UV Irradiation
Rat liver plasma membranes (1 mg of protein/ml) were incubated with 
~1 nM 1 2 5 I-glucagon for 30 minutes at 32°C in a final volume of 400 pi containing 
20 mM NaH2 PC>4 , pH 7.5, 1 mM EDTA, 1 mg/ml BSA, a mixture of protease 
inhibitors [MPI : aprotinin (15 pg/ml), leupeptin (5 pg/ml), and pepstatin (7 
pg/ml)] and, when used, 1 pM unlabelled glucagon. At the end of the incubation, 
the membranes were collected by centrifugation in an Eppendorf centrifuge and 
washed with 20 mM NaH2 P 0 4 , pH 7.5, 1 mM EDTA, 1 mg/ml BSA and MPI 
(500 pi). Pellets were then resuspended in the same buffer minus BSA (350 pi) and 
transferred to a 24-well tissue culture plate. In order to optimise the UV irradiation 
conditions, the plate was placed on ice either 2 cm or 10 cm from a 254 nm UV 
source for 5, 10 or 20 minutes. The result of this experiment (4.2.1.1) led to the 
adoption of 2 0  minutes at 1 0  cm from the source as the irradiation conditions for all 
further cross-linking experiments. After irradiation the membranes were collected 
by centrifugation and stored at -80°C until further use.
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When investigating the effect of the presence of proteins and sugars on 
incorporation of bound hormone into covalently-linked product, ovalbumin, BSA 
and ovomucoid (each at concentrations of 0.1 mg/ml and 1 mg/ml) and GlcNAc and 
galactose (0.2 M) were included in the incubation buffer during the irradiation step 
of the procedure. The result of this experiment (4.2.1.2) led to the use of 
ovalbumin at 1 mg/ml in the irradiation step in all further cross-linking experiments.
2 . 2 . 7  Solubilisation of Membranes Containing Covalently 
Labelled Receptor
Liver membranes that had been cross-linked to 1 2 5 I-glucagon were 
solubilised in 25 mM HEPES, pH 8.0, 1% (w/v) Lubrol-PX (400 pi) at a final 
protein concentration of 1 mg/ml. Samples were incubated on ice for 30 minutes 
with periodic agitation then centrifuged at 100 000 g for 60 minutes. The 
supernatant was removed and used as a source of solubilised glucagon receptor.
2 . 2 . 8  Wheat Germ Agglutinin-Agarose Chromatography of 
Solubilised Covalently Labelled Receptor
A 1 ml column of WG A-agarose was packed in a 2 ml plastic syringe and 
washed with several column volumes of column buffer (25 mM HEPES, pH 8.0, 
0.1% (w/v) Lubrol-PX, 50 mM KC1, 1 mM EDTA, 2mM MgCl2 ) using a 
peristaltic pump with a flow rate set at approximately 0.3 ml/hour. A sample of 
solubilised covalently labelled receptor (2 .2 .6 ) was made up to 1 ml with column 
buffer and applied to the column, which was then washed with column buffer. 
Four fractions of ~ 1.2 ml were collected then fractions of ~0.3 ml were collected 
until they contained no significant radioactivity. Bound material was eluted with
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column buffer containing 0.5 M GlcNAc while continuing to collect fractions of 0.3 
ml, and the amount of radioactivity present in all fractions was measured using a y 
counter. Fractions containing radioactive material eluted by 0.5 M GlcNAc were 
pooled and either precipitated for running on SDS-PAGE or concentrated using 
Centricon-30 microconcentrators for running on isoelectric focusing gels.
2 . 2 . 9  Chloroform/Methanol Precipitation of Proteins
Precipitation of proteins was carried out using the method of Wessel and 
Fliigge (1984). This is a rapid and effective procedure which is unaffected by the 
presence of detergents in the protein sample.
Four volumes of methanol were added to one volume of the protein sample 
and the sample was vortexed and centrifuged at 9000 g for 10 seconds. One volume 
of chloroform was added and the vortexing and centrifugation step repeated. Three 
volumes of water were then added and the sample was vortexed vigorously and 
centrifuged for 1 minute at 9000 g. The upper phase was carefully removed and 
discarded and a further 3 volumes of methanol were added and the sample was 
vortexed and centrifuged for 2 minutes at 9000 g to pellet the protein. The 
supernatant was removed and the protein pellet dried under a stream of air and used 
immediately or stored at -20°C until further use.
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2 . 2 . 1 0  SDS Polyacrylamide Gel Electrophoresis
SDS polyacrylamide gel electrophoresis was performed according to the 
method of Laemmli (1970).
2 . 2 . 1 0 . 1  Casting SDS-Polyacrylamide Gels
A 10% separating gel was prepared using the following components:
10 ml 1.5 M Tris-HCl pH 8 . 8
13.3 ml acrylamide stock
(29% w/v acrylamide, 1% w/v MV'-methylenebisacrylamide)
15.9 ml dH20
400 pi 10% (w/v) ammonium persulphate 
16 pi TEMED
TEMED was added last and the gel poured immediately and overlaid with 
isopropanol. A 5% stacking gel was then prepared using the following components: 
2.5 ml 1 M Tris-HCl pH 6 . 8
3.4 ml acrylamide stock
13.6 ml dH20
2 0 0  pi 1 0 % (w/v) ammonium persulphate 
20 pi TEMED
When the separating gel was set the isopropanol was removed and the top 
of the gel was washed with distilled water. The stacking gel was then poured on 
and the comb inserted.
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2 .2 .1 0 .2  Sample P reparation and Running Conditions
Samples were prepared for running on the gel by adding an equal volume of 
sample buffer (50 mM Tris-HCl, pH 6 .8 , containing 2% (w/v) SDS, 10% (w/v) 
glycerol, 5% (v/v) 2-mercaptoethanol, and 0.1% (w/v) bromophenol blue) or, for 
precipitated proteins, by taking up the proteins in 35 |il of sample buffer. Samples 
were incubated at 37°C for 30 minutes prior to application to the gel. Heating at 
higher temperatures was avoided as this has been shown for certain membrane 
proteins to lead to problems with aggregation and retention of the sample in the 
stacking gel during electrophoresis (Herberg et al., 1984; Hennessey, Jr. and 
Scarborough, 1989). Electrophoresis was earned out using 25 mM Tris containing 
0.19 M glycine and 0.1% (w/v) SDS as running buffer for 3-4 hours at 45 mA. 
Protein bands were visualised by staining with Coomassie blue (2.2.10.3) or silver 
(2.2.10.4).
2 . 2 . 1 0 . 3  Coomassie Blue Staining
After electrophoresis the gel was placed in staining solution (0.04% 
Coomassie brilliant blue R in 10% (v/v) methanol, 10% (v/v) acetic acid) for at least 
1 hour at 40°C, then in destaining solution (10% (v/v) methanol, 10% (v/v) acetic 
acid) until the background was fully destained and bands clearly visible.
2 . 2 . 1 0 . 4  Silver Staining
After electrophoresis the gel was soaked in 50% (v/v) methanol for at least 2 
hours. Solutions A (silver nitrate (0.8 g) dissolved in d ^ O  (4 ml)) and B (14.8 M 
ammonia (1.4 ml) in 0.36% (w/v) NaOH (21 ml)) were prepared and solution A 
was added drop wise to solution B, stirring vigorously. The resulting solution was 
made up to 1 0 0  ml with distilled water and the gel was stained in this solution for
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15 minutes with constant gentle agitation. After washing the gel in distilled water 
for 5 minutes with constant gentle agitation it was placed in developing solution 
(0.005% (w/v) citric acid in 0.019% (v/v) formaldehyde) and agitated. When bands 
were clearly visible the gel was washed several times with water and stored in 50% 
(v/v) methanol.
2 . 2 . 1 0 . 5  Autoradiography
Gels to be autoradiographed were dried and exposed to a sheet of Fuji RX 
medical X-ray film with an intensifying screen at -80°C for 1-20 days.
2 . 2 .1 1  Isoelectric Focusing on Immobilised pH Gradients
(IPG s)
2 . 2 . 1 1 . 1  Rehydration of Immobiline DryPlates
Ready-made Pharmacia-LKB pH 4-7 Immobiline DryPlates were prepared 
for electrofocusing by firstly cutting them into 7 mm wide strips. The strips were 
rehydrated overnight with a solution of 8  M urea containing 0.5-4% (w/v) 
Ampholine pH 3.5-10, 20% (w/v) glycerol and 2% (w/v) Lubrol-PX or NP-40 in 
an LKB reswelling cassette.
2 . 2 . 1 1 . 2  Sample Preparation
Samples for application onto IPGs were solubilised as described in 2.2.7. 
In initial experiments, designed to optimise the procedure by improving sample 
entry and band resolution, solubilised untreated plasma membranes (i.e. 
membranes which had not been subjected to the UV cross-linking procedure) were
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used - in these instances, solubilised samples were prepared for electrofocusing by 
concentrating down to -50 |il in Centricon-30 microconcentrators. However, when 
using solubilised cross-linked membranes, WGA-agarose chromatography was 
performed first and the GlcNAc-eluted fractions and flowthrough fractions were 
pooled separately and concentrated to -50p.l. Urea and Ampholine pH 3.5-10 were 
added to samples at final concentrations of 6  M and 2-4% respectively.
2 . 2 . 1 1 . 3  Focusing
The rehydrated gel strips were lightly blotted with water-saturated filter 
paper and placed on the kerosene-wetted cooling plate of a Pharmacia-LKB 2217 
electrofocusing unit. The electrode strips were soaked with 10 mM glutamic acid 
(anode) and 10 mM sodium hydroxide (cathode). Samples (10 p.1 containing 10-50 
|ig protein) were applied either directly onto the gel surface, in silicone rubber 
frames placed on the gel surface or on Pharmacia-LKB sample application pieces. 
The effect of the sample application position was investigated by applying the 
sample at various points on the gel strips.
After sample application, IPGs were were initially focused at 300-500 V for 
1 hour, thereafter the focusing was performed at 3000 V max and 2 mA max for 5 
hours at a cooling temperature of 15°C using a Pharmacia-LKB 2297 Macrodrive 5 
constant power unit. After focusing the IPG strips were fixed in an aqueous 
solution of 11.5% (w/v) trichloroacetic acid containing 3.5% (w/v) sulphosalicylic 
acid for 30 minutes then stained with either Coomassie blue or silver, or air-dried 
and subjected to autoradiography.
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2 .2 .1 1 .4  Coomassie Blue Staining
Fixed gels were placed in staining solution (0.1% (w/v) Coomassie brilliant 
blue G in 25% (v/v) ethanol and 8 % (v/v) acetic acid) for 30 minutes at 40°C then 
in destaining solution (25% (v/v) ethanol and 8 % (v/v) acetic acid) until the 
background was fully destained and the bands clearly visible. Gels were stored in 
destaining solution or dried.
2 .2 .1 1 .5  Silver S taining
Fixed gels were silver stained using the procedure of Heukeshoven and 
Demick (1985). After 2 x 10 minute washes in 10% (v/v) ethanol and 3 x 10 
minute washes in water the gel was stained in 0.1 % (w/v) silver nitrate for 30 
minutes. After a short rinse with water development was initiated with 2.5% (w/v) 
sodium carbonate solution containing 0.02% (v/v) formaldehyde. Development was 
continued until bands were clearly visible, when the reaction was stopped with 1 % 
(v/v) acetic acid. Three washes with water were followed by brief (10-30 seconds) 
treatment with 0.3% sodium (w/v) thiosulphate containing 0.15% (w/v) potassium 
hexacyanoferrate and 0.05% (w/v) sodium carbonate in order to clear the surface 
and decrease the background. The gel was rinsed for 1 minute under running tap 
water, washed for 3 x 10 minutes in water and stored in water or dried.
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2.2.12 Isoelectric Focusing in Agarose Gels
2 . 2 . 1 2 . 1  Casting Agarose Gels
Agarose gels for isoelectric focusing were cast on 114 x 225 mm sheets of 
GelBond film. A few drops of water were placed on a 114 x 225 mm glass plate 
and a sheet of GelBond film was placed on the plate with the hydrophilic side 
uppermost. The film was rolled flat with a glass rod so that excess moisture and air 
bubbles were removed from under the gel. A second Silane-treated glass plate with 
a rubber spacer attached on three sides was carefully placed on top of the film and 
the two plates were clamped together with spring clips. The mould thus formed was 
warmed in a 60°C incubator before use.
Gels were formed from a solution of 2% (w/v) agarose IEF containing 12% 
(w/v) sorbitol, 3% (w/v) Ampholine pH 3.5-10,1% (v/v) 2-mercaptoethanol,
2% (v/v) NP-40 and 6  M urea. The solution (18 ml per 114 x 225 mm gel) was 
prepared by dissolving the agarose and sorbitol in water by heating in a boiling 
water bath, allowing the mixture to cool to around 70#C then carefully dissolving 
the rest of the components. The solution was then poured into the mould and left 
overnight at room temperature to allow the gel to set fully.
2 . 2 . 1 2 . 2  Sample Preparation
Samples were prepared essentially as described in 2.2.11.2. The effect of 
addition of other detergents to the Lubrol-solubilised sample was studied by adding 
NP-40 or SDS to a final concentration of 2% prior to sample application. The effect 
of solubilisation of membranes in the presence of urea and Ampholine on band 
resolution was investigated by including 6  M urea and Ampholine pH 3.5-10 in the 
solubilisation buffer.
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2 . 2 . 1 2 . 3  Focusing
The gel mould containing the set gel was opened by removing the spring 
clips and carefully prising the two glass plates apart with a spatula. The gel plate 
was removed and placed on the kerosene-wetted cooling plate of a Pharmacia-LKB 
2217 electrofocusing unit. The electrode strips were soaked with 0.5 M acetic acid 
(anode) and 0.5 M sodium hydroxide (cathode). Samples (20 |il containing 20-100 
|ig protein) were applied onto Pharmacia-LKB sample application pieces which had 
been placed on the surface of the gel. The effect of the sample application position 
was investigated by applying the sample at various points between the anode and 
cathode.
After sample application, gels were run at 1000 V max for 90 minutes at a 
cooling temperature of 15°C using a Pharmacia-LKB 2297 Macrodrive 5 constant 
power unit. After focusing the gels were fixed and stained with Coomassie blue.
2 . 2 . 1 2 . 4  Coomassie Blue Staining
Gels were fixed in 33% (v/v) ethanol containing 10% (w/v) trichloroacetic 
acid for 30 minutes then washed with 33% (v/v) ethanol containing 5% (w/v) 
trichloroacetic acid for a further 30 minutes. After a brief rinse in destaining 
solution (35% (v/v) ethanol containing 10% (v/v) acetic acid) gels were placed in 
staining solution (0.2% (w/v) Coomassie brilliant blue R in destaining solution) for 
30 minutes at 40#C then in destaining solution until the background was fully 
destained and bands clearly visible. Gels were stored in destaining solution or 
dried.
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2 .2 .1 3 Solubilisation of Liver Plasma M embranes with CHAPS
Rat liver plasma membranes were suspended at a final concentration of 3-4 
mg protein/ml in 25 mM HEPES, pH 7.5 containing 6  mM CHAPS*, 2 mM 
EDTA, 137 mM NaCl, 0.01 mg/ml aprotinin, 0.005 mg/ml leupeptin, 0.007 mg/ml 
pepstatin and 0.1 mM PMSF. The solubilisation mixture was incubated for 30 
minutes at 4°C with periodic agitation and then spun at 100 000 g for 1 hour at 4°C. 
The supernatant containing soluble active glucagon receptor was used immediately.
*Optimum CHAPS concentration was determined by carrying out the 
solubilisation at 0-40 mM CHAPS (section 3.2.1).
2 .2 .1 4  Assay for CHAPS-soIubilised Glucagon Binding 
A ctivity
CHAPS extract (50-100 pg protein) was incubated with 0.1-0.2 nM 
1 2 5 I-glucagon and, when measuring non-specific binding, 1 pM unlabelled 
glucagon at a final CHAPS concentration of 3 mM in a total volume of 120 pi. 
Incubations were carried out for 2 hours at 4°C then dextran-coated charcoal 
suspension (0.5% (w/v) dextran and 2.5% (w/v) Norit A activated charcoal) (0.4 
ml) was added to each sample. After centrifugation at 2 000 g for 5 minutes, 
aliquots of the supernatants were removed and the radioactivity measured m a y  
counter. Non-specific binding, measured in the presence of 1 pM unlabelled 
glucagon, was typically 1 0 -2 0 % of the total binding.
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2 .2 .1 5 Sucrose Density G radient Centrifugation
CHAPS extract (1 ml) was concentrated to ~200 pi using a Centricon-30 
microconcentrator and 150pl of the concentrated extract was mixed with malate 
dehydrogenase (20 pi of 1 mg/ml; 2600 units/mg), catalase (20 pi of 7 mg/ml; 
18600 units/mg) and /?-galactosidase (10 pi of 10 mg/ml; 315 units/mg). This 
mixture was loaded on a 5-15% sucrose gradient containing 3 mM CHAPS, 2 mM 
EDTA, 137 mM NaCl, 0.01 mg/ml aprotinin, 0.005 mg/ml leupeptin and 0.007 
mg/ml pepstatin. The gradient was centrifuged for 12 hours at 105 000 g in an SW
50.1 rotor at 4°C. After centrifugation, the gradient was fractionated using an 
upwards displacement procedure and approximately 24 fractions of 180 pi each 
were collected. Two 60 pi samples from each fraction were used to assay for 
specific glucagon binding activity, using a half-scale version of 2.2.14. The rest of 
the fraction was used to carry out marker enzyme assays (2.2.16) and protein 
determination (2.2.3).
2 .2 .1 6  M arker Enzyme Assays
M alate Dehydrogenase - the sample (10 pi) was added to 50 mM Tris- 
HCl, pH 7.5,1.5 mM oxaloacetic acid and 43 pM NADH (1 ml) and the decease in 
absorbance at 340 nm after 10 minutes of incubation on ice was noted.
Catalase - the sample (10 pi) was added to 50 mM Tris-HCl, 
pH 7.5, and 5mM hydrogen peroxide (1 ml) and the decrease in absorbance at 240 
nm over a 3-minute period at room temperature was noted.
|3-Galactosidase - the sample (10 pi) was added to 50 mM Tris-HCl, 
pH 7.5, and 2 mM <?-nitrophenyl-/3-D-galactopyranoside (1 ml). The samples were
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incubated at 32°C until a clearly visible yellow colour had developed, at which point 
the reaction was stopped by the addition of 1 M sodium carbonate (0.5 ml). The 
absorbance at 410 nm was noted.
2 .2 .1 7  Gel F iltration
Gel filtration of CHAPS extract was performed on a 0.9 x 25 cm Sepharose 
CL-6 B column which had been equilibrated with, unless otherwise stated, 25 mM 
HEPES, pH 7.5, 2 mM EDTA, 137 mM NaCl and 3 mM CHAPS at 4°C Unless 
otherwise stated, CHAPS extract (1.5 ml) was concentrated to -350 pi using a 
Centricon-30 microconcentrator and the concentrated extract (300 |il) was applied 
to the column and run at a flow rate o f -12 ml/hour. Approximately 70 fractions of 
300 pi each were collected and, for those fractions indicated, two 110 pi samples 
were taken from each fraction and used to assay for specific glucagon binding 
activity. The column was calibrated using the protein standards shown and the void 
volume was determined by the elution of Blue Dextran.
2 .2 .1 8  P reparation  of Immobilised Glucagon (Glucagon-P150)
This procedure was designed to link glucagon covalently through the side 
chain of met-27 to the bromoacetyl derivative of an ethylenediamine substituted 
polyacrylamide gel filtration medium (Bio-Gel P-150) using the procedure of Inman 
(1974). Glucagon-P150 was prepared by Dr. J.G. Beeley.
Bio-Gel P-150 was substituted with ethylenediamine by reaction at 90°C for 
4 hours. The product contained 600 nmoles of amino groups per mg dry weight (as 
determined by titration). The P I50 diamine derivative was coupled with 
bromoacetic acid which had been activated by reaction in the dark with N-
43
hydroxysuccinimide and dicyclohexylcarbodiimide. After washing extensively with 
water the product, bromoacetyl-P150, was dehydrated with methanol and dried 
over KOH pellets.
Bromoacetyl-P150 (250 mg) was allowed to swell in water and then 
washed, by decantation, with 0.1 M acetic acid containing 0.1% (w/v) KI giving a 
final volume of 5 ml. Glucagon (3 mg) dissolved in 0.1 M acetic acid (0.5 ml) was 
added and the reaction mixture was stirred for six days at room temperature in the 
dark. The product was washed extensively with water and 0.5 M NaCl and was 
stored in 0.5 M NaCl containing 1% (w/v) sodium azide at 4#C. The extent of 
coupling was determined by estimation of glucagon remaining in the supernatant 
using the trinitrobenzenesulphonic acid assay for free amino groups described by 
Habeeb (1966).
Glucagon-P150 contained 1-3 nmoles bound glucagon/mg.
2 . 2 . 1 9  Determination of the Binding Capacity of Glucagon- 
P150
The binding capacity of the immobilised glucagon was determined by 
incubating washed glucagon-P150 (0-200 pi packed volume) with CHAPS extract 
(400 pi). In order to carry out the incubations at a final CHAPS concentration of 3 
mM, the appropriate amount of glucagon-P150 was suspended in CHAPS-free 
solubilisation buffer in a final volume of 400 pi, then added to CHAPS extract (400 
pi). Incubations were carried out at 4#C for 2 hours with constant shaking. After 
incubation the samples were centrifuged at 2  0 0 0  g for 1 0  minutes and the 
supernatants were removed. The total specific glucagon binding activity in the 
supernatant was determined by taking four 1 1 0  pi samples for assay and hence the 
percentage of activity bound to the glucagon-P150 was calculated.
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As a result of this experiment (3.4.1), all further experiments were carried 
out using 25 pi (packed volume) of glucagon-P150 per 100 pi of CHAPS extract.
2 .2 .2 0  Affinity C hrom atograpy Using Imm obilised Glucagon
2 .2 .2 0 .1  B inding
CHAPS extract (400-800 pi) was incubated with glucagon-P150 (100-200
pi packed volume) at a final CHAPS concentration of 3 mM for 2 hours at 4°C with 
constant shaking. After incubation the sample was centrifuged at 2 000 g for 10 
minutes, the supernatant was removed and kept for later assay and the glucagon- 
P150 was, unless otherwise stated, washed with 3 mM CHAPS buffer 
(solubilisation buffer containing 3 mM CHAPS in place of 6  mM CHAPS) (1.5 ml) 
and eluted by one of the methods described in 2 .2 .2 0 .2 .
2 .2 .2 0 .2  Elution M ethods
Elution with Glucagon - The washed glucagon-P150 was incubated 
with 3 mM CHAPS buffer containing 10 pM or 100 pM unlabelled glucagon for 1 
hour or overnight at 4°C with constant shaking. The sample was then centrifuged at 
2 000 g for 10 minutes and the supernatant was removed. If assaying samples from 
the supernatant for specific glucagon-binding activity it was necessary to remove 
the unlabelled glucagon. This was attempted using two methods :
i) the supernatant was applied to an 800 pi column of dextran-coated charcoal 
(formed from 3 mM CHAPS buffer containing 2.5% Norit-A activated charcoal 
and 0.5% dextran) and the eluate was assayed for specific glucagon binding 
activity using four 1 1 0  pi aliquots.
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ii) the supernatant was incubated with WGA-agarose (100 p.1 packed volume) for 
2 hours at 4°C. The WGA-agarose was then packed in a 1 ml plastic syringe, 
washed with 3 mM CHAPS buffer (10 ml) and eluted by incubating with 3 mM 
CHAPS buffer (0.6 ml) containing 0.5 M GlcNAc for 2 hours. The eluate was 
assayed for specific glucagon binding activity using four 1 1 0  |il aliquots.
If the supernatant after elution with glucagon was to be characterised by 
SDS-PAGE the proteins present were precipitated using the chloroform/methanol 
method, run on a 10% SDS-polyacrylamide gel and visualised by silver staining.
Elution with Urea - The washed glucagon-P150 was packed in a 1 ml 
plastic syringe and eluted with 3 mM CHAPS buffer (0.6 ml) containing 2 M urea. 
The eluate was dialysed overnight against 3 mM CHAPS buffer (1 litre) and 
assayed for glucagon binding activity using four 1 1 0  p.1 aliquots.
Elution with Low pH Buffers - The washed glucagon-P150 was 
packed in a 1 ml plastic syringe and eluted with 3 mM CHAPS buffer adjusted to 
pH 4 (0.5 ml). The eluate was immediately adjusted to pH 7.5 and assayed for 
glucagon binding activity using four 110 p.1 aliquots. Elution with pH 5 buffer was 
carried out using the same procedure.
Elution with SDS - The washed glucagon-P150 was incubated with 3 
mM CHAPS buffer containing 1% SDS (0.5 ml) for 10 minutes and centrifuged at 
2 000 g for 10 minutes. Proteins present in the supernatant were precipitated using 
the chloroform/methanol method, run on a 10% SDS-polyacrylamide gel and 
visualised by silver staining.
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2 .2 .2 1  Thermostability Experiments
2 . 2 . 2 1 . 1  Thermostability of Membrane-bound Receptor
Liver plasma membrane samples (5-10 pg protein) were incubated with 20 
mM Tris pH 7.5, 5 mM EDTA, 0.01 mg/ml aprotinin, 0.005 mg/ml leupeptin, 
0.007 mg/ml pepstatin and 0.1 mM PMSF in a final volume of 5 pi at 50°C for the 
time intervals indicated. At the end of each time interval four samples were placed 
on ice. All samples were then assayed for glucagon-binding activity as described in 
2.2.5.
2 . 2 . 2 1 . 2  Thermostability of CHAPS-solubilised Receptor
Samples of CHAPS extract (50-100 pg protein) were incubated at 35#C for 
the time intervals indicated. At the end of each time interval four samples were 
placed on ice. All samples were then assayed for glucagon binding activity as 
described in 2.2.14.
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Chapter 3 The CHAPS-solubilised 
Receptor
48
3 .1 Introduction
Treatment of rat liver plasma membranes with CHAPS has been shown to 
yield glucagon receptor in a soluble, active form (Herberg et al., 1984; McVittie and 
Gurd, 1989). However, although conditions for stabilising the receptor have been 
optimised and its binding characteristics studied, isolation of the CHAPS- 
solubilised receptor has still not been achieved. The aims of the work presented in 
this chapter were i) to further optimise the solubilisation and stabilisation of the 
receptor, ii) to further characterise the receptor, using sucrose density gradient 
centrifugation, gel filtration and thermostability techniques, and iii) to isolate the 
receptor using affinity chromatography on immobilised glucagon.
Two assays for CHAPS-solubilised receptor activity have been developed. 
Herberg et al. (1984) utilised the glycoprotein nature of the receptor to develop an 
assay whereby glucagon-receptor complexes bind specifically to wheat germ lectin- 
Sepharose, whereas McVittie and Gurd (1989) used dextran-coated charcoal 
adsorption of free hormone, followed by recovery of glucagon-receptor complexes 
in the supernatant after centrifugation, as the basis of their assay. The latter method 
is superior to the wheat germ lectin method in that it is more rapid, cheaper and 
highly reproducible, and was therefore used to assay for solubilised receptor 
activity throughout the course of the work described in this chapter.
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3 .2 Solubilisation of Active Receptor with CHAPS
3 . 2 . 1  Effect of CHAPS Concentration on the Solubilisation of
Active Receptor
The optimal CHAPS concentration for solubilising active glucagon 
receptors was determined by solubilising liver plasma membranes (4 mg protein/ml) 
as described in section 2.2.13 with a range of CHAPS concentrations (0-40 mM). 
Since adsorption of free glucagon to charcoal requires a CHAPS concentration of 3 
mM or less (McVittie and Gurd, 1989), the CHAPS extracts obtained were diluted 
to a final CHAPS concentration of 3 mM with CHAPS-free solubilisation buffer. 
The diluted extracts were then assayed for specific glucagon binding activity
(2.2.14) and protein (2.2.3). Figure 3.1 shows that both solubilised total protein 
and solubilised active receptor increase with increasing CHAPS concentration. 
However, while there is a large increase in receptor solubilisation between 3 and 6  
mM CHAPS, further increasing the CHAPS concentration results in relatively small 
changes in receptor solubilisation, while protein solubilisation shows a more steady 
rise over the CHAPS concentrations used. For this reason, and in order to 
economise on CHAPS and reduce the scale of dilution required to bring the 
CHAPS concentration of samples to 3 mM, all further solubilisations were carried 
out using 6  mM CHAPS. Figure 3.2 shows that under these conditions the amount 
of specific glucagon binding activity is proportional to the amount of CHAPS- 
solubilised protein assayed.
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Figure 3.1 Effect of CHAPS Concentration on the Solubilisation of 
Active Receptor
Rat liver plasma membranes (4 mg protein/ml) were solubilised in 0-40 mM 
CHAPS in a final volume of 0.5 ml as described in section 2.2.13. The resulting 
CHAPS extracts were diluted with CHAPS-free solubilisation buffer to give a final 
CHAPS concentration of 3mM. Four 110 |il aliquots from each sample were then 
used to assay for specific glucagon-binding activity. The protein concentration of 
each extract was determined as described in section 2.2.3.
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Figure 3.2 Relation of Specific Glucagon Binding to Amount of 
CHAPS-solubilised Protein
CHAPS extract (0-200 pg protein) was assayed for specific glucagon 
binding activity as described in section 2.2.14.
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3 . 2 . 2  Effect of Guanine Nucleotides on Specific Glucagon 
Binding to the CHAPS-solubilised Receptor
The effect of guanine nucleotides on the specific binding of glucagon to the 
CHAPS-solubilised receptor was investigated by carrying out the solubilised 
receptor assay described in section 2.2.14 in the presence or absence of 100 pM 
GTP. It was found that the presence of 100 pM GTP had no effect on the amount 
of specific glucagon binding to the CHAPS-solubilised receptor. This is in contrast 
to the situation for the membrane-bound receptor, where the presence of 100 pM 
GTP resulted in a 50-60% decrease in specific glucagon binding.
3 . 2 . 3  Stability of the CHAPS-solubilised Receptor
A major problem encountered in working with the CHAPS-solubilised 
glucagon receptor is its instability, especially when carrying out lengthy procedures 
such as sucrose density gradient centrifugation or gel filtration. McVittie and Gurd 
(1989) showed that the stability of the receptor was greatly increased by the 
addition of 1 x Hanks' balanced salt solution or, to a lesser extent, 137 mM NaCl in 
the solubilisation buffer. The aim of the following experiments was to further 
increase receptor stability by looking at the effects of calcium and PMSF.
3 . 2 . 3 . 1  Effect of Calcium on Receptor Stability in CHAPS 
Extract
Initial solubilisations of liver plasma membranes with CHAPS were carried 
out with 1.26 mM CaCl2  included in the buffer, since it has been shown that its 
inclusion increases the proportion of specific to total glucagon binding (McVittie 
and Gurd, 1989). However, the effect of calcium on receptor stability is uncertain.
53
Although a divalent ion chelator (EDTA) is present in the solubilisation buffer, the 
activity of calcium-dependent and calcium-stabilised proteases could still present a 
problem. The effect of calcium was investigated by solubilising liver plasma 
membranes with CHAPS in the presence or absence of 1.26 mM CaCl2  as 
described in section 2.2.13. Samples of the extracts were stored for 24 hours at 4°C 
and -80°C and their specific glucagon binding activity was determined and 
compared with the activity measured immediately after solubilisation. Figure 3.3 
shows that after storage at 4°C and, more surprisingly, at -80°C, the loss of 
receptor binding activity was greater in CHAPS extracts containing CaCl2  than in 
those in which the salt was absent. Although the difference at 4°C is small, all 
further solubilisations were therefore carried out without CaCl2  in the solubilisation 
buffer. The proportion of specific to total glucagon binding was found to be 
unaffected by the presence or absence of CaCl2  when 137 mM NaCl was also 
present in the solubilisation buffer.
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Figure 3.3 Effect of Calcium on Solubilised Receptor Stability
Liver plasma membranes (3 mg protein) were solubilised as described in 
section 2.2.13 in the presence or absence of 1.26 mM CaCl2. Four 60 p.1 aliquots of 
the resulting extracts were taken and immediately assayed for specific glucagon 
binding activity as described in section 2.2.14. Aliquots (250 p.1) of the extracts 
were stored at -80°C and 4°C for 24 hours then assayed for specific glucagon 
binding activity. Results are expressed as the percentage of initial activity remaining 
after 24 hours (n = 2).
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3 . 2 . 3 . 2  Effect of PMSF on Receptor Stability in CHAPS 
Extract
Although a mixture of protease inhibitors (aprotinin, leupeptin, pepstatin 
and EDTA) was included in the solubilisation buffer for initial solubilisations 
according to the procedure of McVittie and Gurd (1989), a general protease 
inhibitor cocktail for animal tissue includes PMSF in addition to the inhibitors listed 
above (North, 1989), and it was therefore considered that the inclusion of PMSF in 
the solubilisation buffer might provide the solubilised receptor with additional 
protection from proteases. This was investigated by solubilising liver plasma 
membranes with CHAPS in the presence or absence of 0.1 mM PMSF as described 
in section 2.2.13. Samples of the extracts were stored for 24 hours at 4°C and their 
specific glucagon binding activity was determined (2.2.14) and compared with the 
activity measured immediately after solubilisation. It was found that when 
solubilisation was carried out in the presence of PMSF only 35% of binding activity 
was lost on storage for 24 hours at 4#C whereas when PMSF was absent there was 
a loss of 60% of activity under the same conditions. Therefore all further 
solubilisations were carried out in the presence of 0.1 mM PMSF.
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3 .3 Characterisation of the CHAPS-soIubilised Receptor
3 . 3 . 1  Sucrose Density Gradient Centrifugation
Concentrated (5x) CHAPS extract was centrifuged through 5-15% sucrose 
gradients containing 3 mM CHAPS as described in section 2.2.15. The gradients 
were fractionated by upwards displacement and assayed for specific glucagon 
binding activity (2.2.14) and protein (2.2.3). A typical profile is shown in Figure 
3.4; two peaks of binding activity were routinely seen in the positions shown. 
Standard curves, obtained by plotting the migration distances of marker enzymes 
(run on the same gradient as the CHAPS extract and assayed as described in section 
2.2.16) against their sedimentation coefficients in H2 O, were found to be linear 
and, by interpolation, the two peaks of binding activity were found to represent 
species with sedimentation coefficients of 7.5 ± 0.1 S and 12.9 ± 0.6 S (n = 3). 
These values are somewhat higher than the single value of 4.3 S observed by 
Herberg et al. (1984) for a cross-linked 1 2 5 I-glucagon receptor complex solubilised 
with Lubrol-PX.
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Figure 3.4 Sucrose Density Gradient Centrifugation of CHAPS 
Extract
Concentrated CHAPS extract (150 fil) was run on a 5-15% sucrose gradient 
as described in section 2.2.15. Specific glucagon binding activity was determined 
using two 60 p.1 samples from each 180 fil fraction, using a half-scale version of 
2.2.14, and protein was measured as described in section 2.2.3. The positions of 
marker enzymes, determined using the assays described in 2.2.16, are indicated by 
arrows (MDH = malate dehydrogenase; Cat = catalase; (3-gal = J3-galactosidase).
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3 .3 .2 Gel Filtration on Sepharose CL-6B
Sepharose CL-6 B was used in all gel filtration experiments due to its wide 
fractionation range of 10M  x 106  Da. This fractionation range was desirable 
because, although Herberg et al. (1984) reported a molecular weight of 119 kDa for 
the glucagon receptor in Lubrol-PX, other groups have reported much higher 
molecular weights for the receptor in Lubrol-PX (Giorgio et al.y 1974) and 
digitonin (Mason and Tager, 1985).
Initial experiments were carried out on a 46 ml column. However, using a 
column of this size meant that in order to obtain a manageable number of fractions 
(this being limited by the need to economise on 1 2 5 I-glucagon), the fraction volume 
had to be large ( - 1 . 2  ml) and, keeping the scale of the receptor assay the same as 
described in section 2.2.14, only a small proportion (110 |il) of each fraction could 
be used. As a result of this and the high degree of dilution of sample on the column, 
amounts of activity measured were so small as to be unreliable, especially as 
specific binding represented such a small proportion ( < 1 0  %) of total binding. 
Therefore, a smaller (16 ml) column was used. While the resolution attainable on 
this column was not as high as on the larger one, smaller, more concentrated 
fractions could be collected and hence the receptor assay was more reliable with 
much higher amounts of specific binding detectable. For these reasons the smaller 
column was used for all the experiments described in this section.
As the glucagon receptor is known to be a glycoprotein, its molecular 
weight may not correlate well to the molecular weight calibration curve constructed 
from globular proteins. Therefore a calibration curve relating elution volume to 
Stokes' radius (Rs) was established, the aim being to obtain an Rs value(s) for the 
glucagon receptor and use this, together with a sedimentation coefficient value(s) 
obtained from sucrose density gradient centrifugation, to calculate the molecular 
weight as shown in section 3.3.3, a procedure used previously to determine the 
molecular weight of the receptor in Lubrol-PX (Herberg et al., 1984).
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3 .3 .2 .1 Gel Filtration of Concentrated CHAPS Extract
Concentrated (5x) CHAPS extract was run on Sepharose CL-6 B as 
described in section 2.2.17 and fractions 19-42 were assayed for specific glucagon 
binding activity (2.2.14) and protein (2.2.3). Figure 3.5 shows that the majority 
(-70%) of glucagon binding activity eluted in the void volume, indicating that under 
these conditions much of the solubilised receptor exists in a highly aggregated form 
with a molecular weight of over 4 x 106  Da. However, the fact that lower levels of 
activity are detected over the rest of the range of fractions assayed suggests that 
although the majority of receptor is highly aggregated, a small proportion of the 
total receptor population exists in a series of less aggregated forms. The protein 
profile shows a peak at the void volume but the majority of protein eluted after the 
void volume. This suggests that the aggregation of the receptor is specific to a 
certain degree; i.e. aggregation to the extent seen does not occur simply as a result 
of non-specific aggregation of all or most of the solubilised proteins.
3 . 3 . 2 . 2  Gel Filtration of Unconcentrated CHAPS Extract
Although considered unlikely, it was thought possible that the high degree 
of aggregation of the receptor seen in section 3.3.2.1 could be brought about by 
concentration of CHAPS extract prior to gel filtration. This hypothesis was tested 
by running unconcentrated CHAPS extract on Sepharose CL-6 B as described in 
section 2.2.17 and assaying fractions 19-42 for specific glucagon binding activity
(2.2.14) and protein (2.2.3). Figure 3.6 shows that, as with concentrated extract, 
the majority of activity is eluted in the void volume, although the proportion of the 
total activity in this peak is slightly lower (-60%) than it is with concentrated extract 
(-70%). Thus concentration of CHAPS extract appears to have little effect on 
receptor aggregation, and hence in all the following gel filtration experiments 
concentrated (5x) extract was used due to the higher levels of activity detectable.
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Figure 3.5 Gel Filtration on Sepharose CL-6B of CHAPS Extract
Concentrated CHAPS extract (300 }il) was run on a 0.9 x 25 cm Sepharose 
CL-6 B column as described in section 2.2.17. Fractions (310 pi) were analysed for 
specific glucagon binding activity using two 1 1 0  pi samples (section 2.2.14) and 
for protein (2.2.3). The void volume (Vo) was determined by the elution of Blue 
Dextran.
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Figure 3.6 Gel Filtration on Sepharose CL-6B of Unconcentrated 
CHAPS Extract
CHAPS extract (300 }il) was run on a 0.9 x 25 cm Sepharose CL-6 B 
column as described in section 2.2.17, except that the extract was not concentrated 
prior to application onto the column. Fractions (310 p.1) were analysed for specific 
glucagon binding activity using two 110 |il samples (section 2.2.14) and for protein 
(2.2.3).
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3 .3 .2 .3  Effect of Increased NaCI Concentration on Receptor
Aggregation
Receptor aggregation after solubilisation is most likely to occur as a result of 
hydrophobic interactions. However, in order to eliminate the possibility of 
aggregation through electrostatic interactions, gel filtration was carried out at a 
higher NaCI concentration (637 mM as opposed to 137 mM), although it should be 
added that if aggregation is indeed brought about mainly by hydrophobic 
interactions, an increase in salt concentration could lead to further aggregation. 
CHAPS extract was prepared as described in section 2.2.13 in the presence of 637 
mM NaCI then run on Sepharose CL-6 B as described in section 2.2.17 except that 
the column buffer contained 637 mM NaCI. Fractions 19-40 were assayed for 
specific glucagon binding activity as described in section 2.2.14. It was found that 
the specific activity of CHAPS extract in 637 mM NaCI was approximately one 
third of that in 137 mM NaCI. Figure 3.7 shows that increasing the NaCI 
concentration to 637 mM has no effect on the gel filtration profile, with -70  % of 
activity again eluted in the void volume, and therefore has no effect on receptor 
aggregation. All further experiments were carried out in 137 mM NaCI.
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Figure 3.7 Gel Filtration on Sepharose CL-6B of CHAPS Extract in 
High Salt
CHAPS extract (1.5 ml) was prepared as described in section 2.2.13, 
except that the concentration of NaCI was 637 mM. After concentration to 300 |il 
the extract was run on a 0.9 x 25 cm Sepharose CL-6 B column as described in 
section 2.2.17, except that the column buffer contained 637 mM NaCI. Fractions 
were assayed for specific glucagon binding activity using two 1 1 0  |il samples 
(section 2.2.14).
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3 .3 . 2.4 Effect of Sucrose on Receptor Aggregation
The results of experiments 3.3.2.1-3.3.2.3, suggesting a high degree of 
receptor aggregation in CHAPS extract, contradict the result obtained from sucrose 
density gradient centrifugation (3.3.1) which identifies much smaller glucagon- 
binding species, as evidenced by their sedimentation coefficients. It was therefore 
considered that sucrose might prevent receptor aggregation or, because CHAPS 
extracts applied to sucrose gradients were prepared in the absence of sucrose, that it 
might promote disaggregation of the receptor. This was tested by preparing 
CHAPS extract as described in section 2.2.13 and making it 10% (w/v) with 
respect to sucrose prior to gel filtration using column buffer containing 1 0 % (w/v) 
sucrose. Fractions 19-40 were assayed for specific glucagon binding activity. The 
proportion of activity in the void volume peak was found to be lower (~50% of the 
total activity) in the presence of sucrose (Figure 3.8) than in its absence (3.3.2.1), 
suggesting at least a small degree of disaggregation in the presence of sucrose.
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Figure 3.8 Gel Filtration on Sepharose CL-6B of CHAPS Extract in 
10% Sucrose
Concentrated CHAPS extract was made 10% (w/v) with respect to sucrose 
and 300 jil was run on a 0.9 x 25 cm Sepharose CL-6 B column as described in 
section 2.2.17, except that the column buffer also contained 10% (w/v) sucrose. 
Fractions were assayed for specific glucagon binding activity using two 110 |xl 
samples (section 2.2.14).
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3 .3 .2 .5  Effect of Increased Spin Time in Preparation of CHAPS
Extract on Gel Filtration
Experiment 3.3.2.4, although showing that sucrose has a small effect on the 
aggregation state of the receptor, does not explain why still 50% of active receptor 
appears to be highly aggregated while sucrose density gradient experiments do not 
give any evidence of the receptor in such a high state of aggregation. It was 
considered that the spin conditions in the sucrose density gradient experiments (105 
0 0 0  g for 1 2  hours) could result in highly aggregated material of the size suggested 
by gel filtration experiments being pelleted and so undetected after fractionation of 
the gradient. Therefore, CHAPS extract was prepared as described in section 
2.2.13 except that the solubilisation mixture was spun at 105 000 g for 12 hours 
instead of at 100 000 g for 1 hour. The concentrated extract was then run on 
Sepharose CL-6 B as described in section 2.2.17 and fractions 20-47 were assayed 
for specific glucagon binding activity as described in section 2.2.14, using a higher 
concentration (0.5 nM) of 1 2 5 I-glucagon than normal due to the expected low 
amounts of activity present. Figure 3.9 shows that no activity eluted in the void 
volume, indicating that the high molecular weight material seen in the previous 
experiments was indeed pelleted using the longer centrifugation. The implications 
of this for the solubilisation of the glucagon receptor with CHAPS are discussed in 
section 5.1.1. Figure 3.9 also shows a peak of binding activity at an elution volume 
of ~10.4 ml; this was routinely observed as the peak of lowest molecular weight but 
no other peaks could be resolved. A calibration curve was obtained by plotting V - 
log (Kav) against Rs where
Kav = Ve_Vo
Vt-Vo
where Ve = elution volume for the protein 
V0  = column void volume 
Vt -  total bed volume
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The calibration curve obtained was linear and gave an Rs value of 5.8 nm 
for the species giving the peak of activity shown in Figure 3.9. This compares with 
a value of 6.3 nm obtained by Herberg et al. (1984) for a cross-linked 1 2 5 I- 
glucagon-receptor complex solubilised in Lubrol-PX.
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Figure 3.9 Gel Filtration on Sepharose CL-6B of CHAPS Extract 
Spun at 105 000 g for 12 Hours
CHAPS extract (1.5 ml) was prepared as described in section 2.2.13, 
except that the solubilised membranes were spun at 105 000 g for 12 hours. After 
concentration to 250 |il the extract was made 10% (w/v) with respect to sucrose and 
300 p.1 of concentrated extract was run on a 0.9 x 25 cm Sepharose CL-6 B column 
as described in section 2.2.17, except that the column buffer also contained 10% 
(w/v) sucrose. Fractions were assayed for specific glucagon binding activity using 
two 110 pi samples (section 2.2.14). The elution positions of calibration proteins 
are indicated by arrows (Aid = aldolase; Cat = catalase; Fer = ferritin; Thy = 
thyroglobulin).
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3 .3 .3  Estimation of the Minimum Molecular Weight of the
CHAPS-solubilised Receptor
The gel filtration experiments described in section 3.2 show that, under the 
solubilisation conditions used, the majority of the glucagon receptor population 
exists in a highly aggregated form which can be pelleted by increasing the time and 
rate of centrifugation during preparation, while a smaller proportion appears to be 
present as a series of less aggregated species. By using the sedimentation 
coefficient foo,©) and Stokes radius (Rs) values of the smallest species given by 
sucrose density gradient and gel filtration experiments, and assuming that these 
correspond to the same species, it was possible to estimate a minimum molecular 
weight for the receptor under these conditions using the following equation,
Mf =  67tNq 20,0) • Rs • S20.G)
(1 - Vp20,co)
where v (partial specific volume (ml/g)) was assumed to be 0.738, the average for 
all the marker proteins and thus an additional assumption is made that, as has been 
observed for the receptor in Lubrol-PX (Herberg et al., 1984), there is no 
significant binding of detergent to the receptor. As the partial specific volume of 
CHAPS (0.75) is very similar to this value, running of CHAPS extract on sucrose 
gradients containing D2 O was not carried out since no change in the observed 
sedimentation coefficient of the receptor due to detergent binding would have been 
observed and hence this would not have been a suitable method for determining the 
true partial specific volume (for further discussion see section 5.1.2). The minimum 
molecular weight was calculated to be approximately 190 kDa and it is that the 
smallest form of the receptor in 6  mM CHAPS is a trimer of the 60 kDa species 
seen in cross-linking studies (see section 5.1.2 for discussion).
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3 .3 .4  Effect of CHAPS Concentration on Receptor
A ggregation
It was shown in section 3.2.1 that increasing the CHAPS concentration 
above 6  mM has little effect on the amount of active receptor solubilised from liver 
plasma membranes. However, it is possible that an increase in CHAPS 
concentration,whilst having no effect on the quantity of receptor solubilised, may 
have an effect on the aggregation state of the receptor that is solubilised and thus the 
proportion of solubilised activity that exists in the highly aggregated form seen in 
gel filtration experiments (3.3.2). To test this, liver plasma membranes were 
solubilised as described in section 2.2.13 using CHAPS concentrations of 6  mM 
and 20 mM. The resulting extracts were then centrifuged at 105 000 g for 12 hours 
in order to pellet highly aggregated material as shown in section 3.3.2.5. The 
supernatants were diluted to 3 mM CHAPS and assayed for specific glucagon 
binding activity as described in section 2.2.14. It was found that the percentage of 
activity remaining in the supernatant was unaffected by the CHAPS concentration 
(19.7% and 17.2% in 6  mM and 20 mM CHAPS respectively), indicating that the 
aggregation state of the solubilised receptor is unaffected by changes in CHAPS 
concentration.
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3 .3 .5  Thermostability of the CHAPS-soIubilised Receptor
The effect of heat on the binding activity of the CHAPS-solubilised receptor 
was investigated for possible further evidence of receptor heterogeneity. 
Preliminary experiments, carried out to determine a temperature at which <10% of 
the initial specific glucagon binding activity in CHAPS extract was present after a 
suitable time interval, led to the adoption of 35°C as the temperature used in all 
thermostability experiments involving the CHAPS-solubilised receptor.
A timecourse for the thermostability of the receptor in CHAPS extract was 
carried out as described in section 2.2.21.2. Figure 3.10 shows that biphasic decay 
of receptor binding activity was observed : a rapid loss of binding activity was seen 
over the first 30 minutes (22% of activity remaining), followed by a much slower 
decrease so that 18% of activity still remained after 60 minutes. This suggests that 
there are two receptor populations with differing thermostability, one accounting for 
~75% of the total population, with a half-life of ~9 minutes at 35°C, and the other 
accounting for ~25%, with a half-life of ~128 minutes at 35#C. The inclusion of 
100 |iM  GTP in the incubation mixture had no effect on the observed 
thermostability. Similar experiments using liver plasma membranes, carried out as 
described in section 2.2.21.1, showed monophasic decay (Figure 3.11), 
suggesting the presence of a homogeneous receptor population with a half-life of ~7 
minutes at 50°C (it should be noted that thermostability experiments involving 
membranes were performed at 50°C, reflecting the greater stability of the receptor in 
membranes compared with the CHAPS-solubilised receptor). It is therefore 
possible that the results observed with CHAPS extract were not due to the 
thermostability of the glucagon receptor but to changes in some other constituent(s) 
of CHAPS extract (discussed in section 5.1.2). Since the relative proportions of the 
two receptor populations in CHAPS extract with differing thermostability correlate 
approximately with the proportions of receptor of high or low aggregation state, it 
was proposed that the observed biphasic decay of the receptor in CHAPS extract
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might be a reflection of the aggregation state of the receptor, with the highly 
aggregated form(s) having a lower thermostability than the less highly aggregated 
forms. This hypothesis was tested by carrying out a timecourse for the 
thermostability of the receptor in CHAPS extract which had been spun at 105 000 g 
for 12 hours (see section 3.3.2.5); i.e. using only ’less aggregated1 receptor. 
However, reliable assessment of the specific glucagon binding activity of this 
material was not possible due to a high proportion (>80%) of non-specific binding 
in a small amount of total binding, especially after any heat treatment.
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Figure 3.10 Thermostability of CHAPS-solubilised Receptor
Samples of CHAPS extract (50-100 |ig protein) were incubated at 35°C for 
the time intervals shown and assayed for specific glucagon binding activity as 
described in section 2.2.14. Results are expressed as the log of the percentage of 
initial binding activity remaining after each time interval (n=4).
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Figure 3.11 Thermostability of Membrane-bound Receptor
Liver plasma membranes were incubated at 50°C for the time intervals 
shown as described in section 2 .2 .2 1 . 1  and assayed for specific glucagon binding 
(2.2.14). Results are expressed as the log of the percentage of initial binding 
activity remaining after each time interval (n=2 ).
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3 .4 Affinity Chrom atography Using Immobilised Glucagon
Immobilised glucagon (glucagon-P150) was prepared as described in 
section 2.2.18. Specific binding of CHAPS-solubilised receptor to glucagon-P150 
was demonstrated by incubating CHAPS extract with either glucagon-P150 or 
bromoacetyl-P150 (the activated P I50 derivative to which glucagon had not been 
coupled) for two hours at 4°C with constant shaking at a final CHAPS 
concentration of 3 mM. After centrifugation, the supernatants were assayed for 
specific glucagon binding activity as described in section 2.2.14. Table 3.1 shows 
that binding of receptor activity to glucagon-P150 is specific as 83% of activity was 
shown to bind to it whereas only 2 % of activity was bound to the bromoacetylated 
derivative.
3 .4 .1  Determination of the Binding Capacity of Glucagon-
P150
The binding capacity of the immobilised glucagon was determined as 
described in section 2.2.19. Figure 3.12 shows that, using 400 pi of CHAPS 
extract, the amount of activity bound is proportional to the packed volume of 
glucagon-P150 up to a volume of approximately 100 |il. At volumes above this 
value 100 % of activity was found to be bound. Therefore in all further experiments 
25 pi (packed volume) of glucagon-P150 per 100 pi of CHAPS extract was used.
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INCUBATION SPECIFIC  
BINDING  
ACTIVITY IN 
SUPERNATANT  
(cpm)
ACTIVITY 
BOUND TO P150 
DERIVATIVE 
(cpm)
CHAPS extract 13 400
CHAPS extract + 
glucagon-P150 2 300 (17%) 11 100 (83%)
CHAPS extract + 
bromoacetyI-P150 13 100 (98%) 300 (2%)
Table 3.1 Specific Binding of CHAPS-solubilised Receptor 
Activity to Glucagon-P150
CHAPS extract (500 pi) was incubated with glucagon-P150 or 
bromoacetyl-P150 (100 pi packed volume), or with no additions, at a final CHAPS 
concentration of 3 mM at 4°C for 2 hours. After centrifugation , 4 x 110 pi aliquots 
of the supernatants were assayed for specific glucagon binding activity as described 
in section 2.2.14. The figures in brackets represent the percentage of the total 
binding activity with which the P I50 derivatives were incubated.
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Figure 3.12 Determination of the Binding Capacity of 
GIucagon-P150
The binding capacity of glucagon-P150 was determined as described in 
section 2.2.19. Results are expressed as the percentage of activity present in 400 p.1 
of CHAPS extract bound to glucagon-P150.
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3 .4 .2 Elution of Active Receptor from GIucagon-P150
Sections 3.4 and 3.4.1 show that the glucagon-P150 we prepared bound the 
CHAPS-solubilised receptor specifically and in a manner proportional to the 
amount of immobilised ligand present. The experiments presented in this section 
describe the results of various methods which were used to elute the receptor from 
glucagon P-150 in an active form. In all these experiments, unless otherwise stated, 
the receptor was bound to glucagon-P150 and the resulting glucagon-P 150-receptor 
complex was washed as described in section 2 .2 .2 0 . 1 .
3 .4 .2 .1  Elution with Glucagon
The method of choice for elution of the bound receptor from glucagon-P 150 
is elution with glucagon itself because of the potentially high degree of specificity 
afforded by this method. However, in order to be able to assay for specific 
glucagon binding after elution, the unlabelled glucagon in the eluate must be 
removed, or at least its concentration must be reduced to such a level that it does not 
interfere with the assay. By using a competition binding assay curve for CHAPS 
extract (McVittie and Gurd, 1989) it could be seen that an unlabelled glucagon 
concentration of 1 nM or lower would be required in order to achieve this. 
However, if elution was carried out using 10 pM glucagon, simple dilution of the 
eluate to 1 nM glucagon was obviously not feasible due to the very large scale of 
dilution required. Therefore it was necessary to use other methods, described 
below. In each case the washed glucagon-P 150-receptor complex was incubated 
with 10 pM glucagon for one hour at 4°C with constant shaking then centrifuged at 
2  0 0 0  g for ten minutes, after which the supernatant was removed and treated for 
removal of glucagon before assaying for specific glucagon binding activity.
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ii) Removal of Glucagon using Wheat Germ Agglutinin - Agarose
It has been shown previously that the CHAPS-solubilised receptor can be 
bound reversibly to wheat germ agglutinin (Herberg et al., 1984). Therefore it was 
considered that incubation of glucagon-eluted material with excess WGA-agarose 
followed by extensive washing could be an effective way of removing glucagon 
from the eluate. The WGA-agarose-receptor complex could then be eluted with 
GlcNAc and assayed.
In order to determine the volume of wash buffer required to reduce the 
concentration of glucagon to below 1 nM a preliminary experiment was carried out 
whereby 0.5 ml (i.e. the same volume as used to elute glucagon-P 150) of 10 |iM 
unlabelled glucagon containing a small amount (-250 000 cpm) of 1 2 5 I-glucagon as 
a tracer was incubated with 100 |il of packed WGA-agarose which was then packed 
in a 1 ml plastic syringe and washed with varying amounts of 3 mM CHAPS buffer 
before elution with 0.5 M GlcNAc. Assuming that the proportion of unlabelled 
glucagon in the eluate was equivalent to the proportion of 1 2 5 I-glucagon present, it 
was found that a wash of at least 1 0  ml was required to bring the concentration of 
unlabelled glucagon to below 1 nM in the GlcNAc-eluted fraction and therefore this 
volume was routinely used in the washing step of the procedure.
Supernatants after glucagon-elution were treated with WGA-agarose as 
described in section 2.2.20.2. However, no specific glucagon binding activity was 
recovered using this method. In order to investigate possible reasons for this an 
experiment was carried out whereby CHAPS extract was incubated with WGA- 
agarose in the presence or absence of 10 |iM glucagon for two hours at 4°C. The 
WGA-agarose was then packed in a 1 ml plastic syringe and washed and eluted as 
described in section 2.2.20.2. It was found that no activity was present in the 
eluate, regardless of whether the CHAPS extract initially contained 10 |iM glucagon 
or not, suggesting that the receptor was either being lost during the washing step 
before elution, or that it was remaining bound to the WGA-agarose during the
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elution step. This was investigated further by varying (i) the wash volume and (ii) 
the elution time. Samples of CHAPS extract were incubated with 100 p.1 (packed 
volume) of WGA-agarose at 4°C for two hours, then washing and elution were 
carried out as shown in Table 3.2. This table shows that
i) when a 10 ml wash was used, no receptor activity was eluted with GlcNAc 
whereas the use of a 1 ml wash resulted in the elution of 56% and 52% of bound 
activity after two and twenty hours respectively, and
ii) increasing the elution time from two to twenty hours had no effect on the amount 
of activity eluted by GlcNAc.
These results suggest that activity bound to WGA-agarose is lost during a 10 ml 
washing step. This problem could be overcome by reducing the volume of buffer 
used to wash the WGA-agarose; however, this was not possible since a wash of at 
least 1 0  ml was required to give a sufficiently low glucagon concentration. 
Therefore this method of removing glucagon after elution from glucagon was 
considered unfeasible.
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TREATMENT ACTIVITY 
RECOVERED (%)
1 ml wash, 2 hr elution 56
10 ml wash, 2 hr elution 0
1 ml wash, 20 hr elution 52
10 ml wash, 20 hr elution 0
Table 3.2 Effect of Washing Volume and Elution Time on 
Recovery of Active Receptor from WGA-agarose
CHAPS extract was incubated with 100 pi (packed volume) of WGA- 
agarose at 4°C for 2 hours. The WGA-agarose was then washed with the volume of 
3 mM CHAPS buffer shown and incubated with 0.5 M GlcNAc (0.5 ml) for the 
time interval shown. Eluates were then assayed for specific glucagon binding 
activity as described in section 2.2.14. Results are expressed as the percentage of 
activity eluted compared with untreated CHAPS extract assayed at the appropriate 
time intervals.
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ii) Removal of Glucagon bv Dextran-coated Charcoal Treatment
This method was based on the principle of the solubilised receptor assay; 
i.e. utilising dextran-coated charcoal to adsorb free glucagon. Supernatants after 
glucagon-elution were run through 800 p.1 charcoal-dextran columns and assayed 
for specific glucagon binding activity as described in section 2.2.20.2 (i). In order 
to ensure that this method would reduce the concentration of glucagon to the 
necessary level a preliminary experiment was carried out whereby 0.5 ml (i.e. the 
same volume as used to elute glucagon-P150) of 10 |xM unlabelled glucagon 
containing a small amount (400 000 cpm) of 1 2 5 I-glucagon as a tracer was run 
through a column of dextran-coated charcoal of either 2 0 0  |il or 800 p.1 which had 
previously been washed with 3 mM CHAPS buffer. The eluate was then counted 
for 1 2 5 I. Assuming that the proportion of unlabelled glucagon removed by the 
column was equivalent to the proportion of 1 2 5 I-glucagon tracer removed, it was 
found that a 2 0 0  |il charcoal column was effective in reducing the glucagon 
concentration in the eluate from 10 |iM to 30 nM whereas using an 800 |il column it 
was possible to reduce the concentration to ~0.8 nM which was thus deemed 
sufficient to enable the glucagon binding assay to be performed. However, 
treatment of supernatants after glucagon-elution by such a method resulted in the 
recovery of no specific glucagon binding. At this stage it was impossible to say 
whether the failure to recover activity was due to the receptor not being eluted by 
glucagon under the conditions used or to the receptor losing activity during the 
elution process.
The experiments described above have shown that while it is possible that 
failure to detect receptor activity after elution with glucagon may have been due to 
loss of activity during the treatments to remove glucagon from the eluate, it is 
equally possible that it may have been due to failure to elute the receptor from 
glucagon-P150 using glucagon. This hypothesis was tested by carrying out elutions
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as described in section 2.2.20.2 using 100 |iM  glucagon (i.e. lOx the concentration 
used in previous experiments) and using incubation times of one and twenty hours. 
Proteins in the supernatants after elution were precipitated by the chloroform/ 
methanol method described in section 2.2.9 and characterised by running on 10% 
SDS-PAGE gels (2.2.10). Using the figure quoted by M cVittie and Gurd (1989) 
for the am ount o f glucagon receptor in CHAPS extract (at least 200 fmol/mg 
CHAPS extract protein) it was calculated that if 800 pi o f CHAPS extract was used 
at the start of an affinity chromatography experiment, and assuming that 100% of 
receptor activity was bound to the glucagon-P150, there would be enough receptor 
present to be visualised by silver staining, even if a relatively small proportion, e.g. 
20%, was eluted from the glucagon-P150 (see section 5.1.3). However, no bands 
were seen on silver stained gels after carrying out the procedure described above, 
indicating that elution o f the receptor with glucagon was not achieved, even after 
using 100 pM  glucagon and incubating for 20 hours.
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3 . 4 . 2 . 2  E lu tion  wi th U rea
The effect of urea on the specific glucagon binding activity of the CHAPS- 
solubilised receptor was investigated by carrying out the assay described in section 
2.2.14 in the presence of 0-1 M urea. Figure 3.14 shows that specific binding 
decreases with increasing urea concentration so that in the presence of 1 M urea 
only 7% of activity remains. In order to see if this loss of activity was reversible, 
CHAPS extract was incubated with 2 M urea then dialysed overnight against 3 mM 
CHAPS buffer at 4°C. The specific glucagon binding activity was then determined. 
It was found that 45% (taking the activity of untreated CHAPS extract left at 4°C 
overnight as 100%) of activity was recovered after dialysis. Therefore an elution 
strategy was devised whereby the glucagon-P 150-receptor complex was eluted with 
2 M urea and dialysed as described in section 2.2.20.2. However, it was found that 
no activity was recovered in the dialysate after this procedure. Possible reasons for 
this are discussed in section 5.1.3.
3 .4 .2 .3  Elution with Low pH Buffers
A final attempt to elute the receptor from glucagon-P 150 in an active form 
was made using low pH buffers, using the procedure described in section 
2.2.20.2. Care was taken to ensure that the eluate was at low pH for as little time as 
possible by eluting into buffer containing the appropriate volume of 1 M Tris base 
required to bring the pH back to 7.5. However, specific glucagon binding activity 
was not recovered using either pH 4 or pH 5 buffers. Possible reasons for this are 
discussed in section 5.1.3.
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Figure 3.13 Effect of Urea on Solubilised Receptor Binding Activity
Specific glucagon binding activity in CHAPS extract was measured in the 
presence of the indicated concentrations of urea, using the assay described in 
section 2.2.14.
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3 .4 Elution of Receptor from GIucagon-P150 with SDS
As elution of the active receptor had not been achieved using the methods 
described in sections 3.4.2.1-3.4.2.3 elution with SDS was carried out; obviously 
this would not result in the elution of active receptor but would give some indication 
of the specificity of binding of the receptor to glucagon-P150 and therefore an 
indication of the potential degree of purification afforded by this method.
CHAPS extract was incubated with glucagon-P 150 and washed as 
described in section 2.2.20.1. As a control, CHAPS extract was incubated with 
bromoacetyl-P150 using a similar procedure. The P I50 derivatives were then eluted 
with SDS as described in section 2.2.20.2. Figure 3.14 (lanes 5 and 8 ) shows that 
the SDS-eluted material from both glucagon-P150 and bromoacetyl-P150 contained 
the majority of proteins originally present in the CHAPS extract (these lanes are 
somewhat overloaded due to the unexpectedly high amount of protein present in the 
eluates). The inclusion of two additional washing steps, one of them with an 
increased NaCl concentration (1 M), before elution, had no effect on the band 
pattern seen on silver stained SDS-PAGE gels (Figure 3.15), and the high salt 
wash (lane 2 ) contained very little protein.
These results showed that elution with SDS was not suitable as a method 
for elution of the receptor from glucagon-P 150 due to the simultaneous elution of 
non-specifically bound proteins which could not be removed by washing in high 
salt. Therefore, due to the unsuitability of this elution method, and of those elution 
methods described previously, this line of research was discontinued.
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Figure 3.14 SDS-PAGE of SDS-eluted Material from Glucagon- 
P150 and Bromoacetyl-P150 After Incubation With 
CHAPS Extract
CHAPS extract (800 |il) was incubated with glucagon-P150 (200 |il) or 
bromoacetyl-P150 (200 p.1) and centrifuged as described in section 2.2.20.1. The 
affinity matrix was then washed (2.2.20.1) and eluted with SDS (2.2.20.2). The 
samples listed opposite were run on a 10% SDS polyacrylamide gel and silver 
stained (2 .2 . 1 0 ).
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Lane 1 : molecular weight markers
2: CHAPS extract
3: supernatant after incubation of glucagon-P 150 with CHAPS extract
4: wash of glucagon-P 150 after incubation with CHAPS extract
5: SDS-eluted material from glucagon-P 150 after incubation with
CHAPS extract and washing 
6: supernatant after incubation of bromoacetyl-Pl 50 with CHAPS
extract
7: wash of brom oacetyl-Pl50 after incubation with CHAPS extract
8: SDS-eluted material from bromoacetyl-Pl50 after incubation with
CHAPS extract and washing
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Figure 3.15 SDS-PAGE of SDS-eluted M aterial from Glucagon-P150
CHAPS extract (800 |il) was incubated with glucagon-P 150 (200 jxl) and 
centrifuged as described in section 2.2.20.1. The affinity matrix was then washed 
as described in section 2 .2 .2 0 . 1  but with the inclusion of two additional washing 
steps, one of them with high salt (1 M NaCl), and eluted with SDS (2.2.20.2). The 
samples listed opposite were run on a 10% SDS polyacrylamide gel and silver 
stained (2 .2 . 1 0 ).
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1 2 3
Lane 1: 
2:
3:
supernatant after incubation of CHAPS extract with glucagon-P 150 
high salt wash of glucagon-P150 after incubation with CHAPS 
extract
SDS-eluted material from glucagon-P150 after incubation with 
CHAPS extract and washing
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3 .5  Summary
Solubilisation of rat liver plasma membranes with CHAPS yielded glucagon 
receptor in an active form. Increases in CHAPS concentration above 6  mM resulted 
in no further increase in solubilised activity as measured by a charcoal/dextran 
binding assay, suggesting the possibility of conformational denaturation of the 
receptor at higher detergent concentrations. This aspect of receptor solubilisation, 
and the subsequent stability of the solubilised receptor, are discussed in section 
5.1.1.
Size characterisation of the CHAPS-solubilised receptor was carried out by 
the combined use of sucrose density gradient centrifugation and gel filtration. These 
methods showed the receptor to exist predominantly in a highly aggregated form in 
CHAPS. This aggregation appeared to be specific and was unaffected by changes 
in ionic strength or CHAPS concentration. Removal of highly aggregated material 
allowed the identification of a 190 kDa species as the smallest species present in 
CHAPS and this is proposed to be a trimer of receptor subunits. This and aspects 
of receptor aggregation are discussed in section 5.1.2.
Thermostability studies on the CHAPS-solubilised receptor showed 
biphasic decay of binding activity at 35°C. This is discussed in section 5.1.2 in 
terms of the possibility of the existence of heterogeneous receptor populations.
Binding of CHAPS-solubilised receptor to immobilised glucagon was 
shown. However, elution with glucagon, urea or low pH buffers did not result in 
elution of active receptor, while SDS-PAGE analysis of glucagon-eluted material 
showed no elution of receptor even at higher glucagon (concentrations and increased 
time of elution. Elution with SDS resulted in the elution of proteins which were 
presumably bound non-specifically to the immobilised glucagon. These results are 
discussed in section 5.1.3.
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Chapter 4 Receptor Desensitisation 
and Phosphorylation
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4.1 In troduction
As described in section 1.7, treatment of intact hepatocytes with glucagon, 
or other ligands which stimulate inositol phospholipid metabolism, leads to a 
cAMP-independent desensitisation of glucagon-stimulated adenylate cyclase 
activity. As this process is mimicked by the phorbol ester TPA it has been proposed 
that protein kinase C plays a crucial role in the mechanism of desensitisation, 
bringing about the phosphorylation of either the glucagon receptor or the 
stimulatory guanine nucleotide regulatory protein Gs, or both of these components 
(Murphy et al., 1987). The aim of the experiments described in this chapter was to 
ascertain whether phosphorylation of the glucagon receptor takes place during the 
desensitisation process, as has been shown for other receptors.
The |3-adrenergic receptor was shown to be phosphorylated during 
desensitisation by incubating cells in the presence of 3 2 P-labelled ATP, both before 
and during the desensitisation procedure, purifying the receptor and identifying it as 
a 3 2 P-labelled protein on SDS-PAGH (Nambi et al., 1985 ). However, the use of a 
similar procedure to identify phosphorylation of the glucagon receptor during 
desensitisation was not possible due to the unavailability of a procedure to purify 
the receptor to homogeneity. Therefore the following methods were used: i) 
isoelectric focusing of partially purified covalently labelled 1 2 5 I-glucagon-receptor 
complex on immobilised pH gradients and agarose IEF gels, and ii) comparison of 
the thermostability of the receptor in membrane fractions prepared from control and 
desensitised hepatocytes.
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4 .2 Isoelectric Focusing of Glucagon Receptor
Phosphorylation of the receptor would bring about a change in its isoelectric 
point and hence its focused band position on isoelectric focusing gels. Therefore, if 
the receptor was labelled by covalent cross-linking to 1 2 5 I-glucagon, it would be 
possible to distinguish between phosphorylated and unphosphorylated receptor by 
running solubilised cross-linked membrane preparations on isoelectric focusing gels 
without the need for purification of the receptor to homogeneity. However, before 
this could be carried out using membrane preparations from control and 
desensitised cells, it was necessary to optimise both the cross-linking procedure and 
the isoelectric focusing of solubilised membranes.
4 . 2 . 1  Direct Cross-linking of 125I-glucagon to Liver Plasma
Membranes by UV Irradiation
Iwanij and Hur (1985) showed that cross-linking of 1 2 5 I-glucagon to its 
receptor in plasma membranes could be achieved directly by UV irradiation, 
without the need for photoaffinity reagents. Using this procedure they identified a 
labelled glucagon-receptor complex of Mr 62 kDa. However, the amount of 
membrane-bound 1 2 5 I-glucagon incorporated into the cross-linked complex was 
low (0.5-1.2%). The following experiments were carried out to try to improve the 
incorporation by varying the UV irradiation conditions used and investigating the 
effect of protein and sugar additives on cross-linking.
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4 .2 .1 .1 Effect of UV Irradiation Conditions on Cross-linking
Liver plasma membranes were incubated with 1 2 5 I-glucagon and UV 
irradiated as described in section 2.2.6, carrying out the irradiation for 5,10 and 20 
minutes with the sample either 2 cm or 10 cm from the 254 nm UV source. The 
samples were then analysed by SDS-PAGE and autoradiography (2.2.10). Figure
4.1 shows the incorporation of label into a band of Mr ~60000., correlating well 
with the results obtained by Iwanij and Hur (1985) using a similar procedure. The 
specificity of labelling of this band is shown by its abolition when binding and 
cross-linking were carried out in the presence of 1 |iM unlabelled glucagon (lanes 4 
and 8 ). The incorporation of label into this band was quantitated by excising the 
corresponding areas of the dried gel and counting them for 1 2 5 I. Figure 4.2 shows 
that at both UV source distances incorporation of label into the 60 kDa receptor 
band increased with increasing time of UV irradiation and that incorporation at each 
time point was greater with the UV source at 2 cm than at 10 cm. Figure 4.1 shows 
that, with the UV source at 2 cm from the sample, increasing time of irradiation led 
to an increase in the appearance of labelled material of higher molecular weight, 
including a band at ~170 kDa which may represent a trimeric aggregate of the 
receptor. Under these conditions, labelled material was also retained by the stacking 
gel (not shown). These aggregates were seen to a lesser extent with the UV source 
at a distance of 1 0  cm from the sample, even with an irradiation time of 2 0  minutes. 
Therefore, irradiation conditions adopted for use in future experiments were 20 
minutes at a distance of 10 cm from the UV source; although the amount of label 
incorporated into the 60 kDa band was lower using this regime than with a similar 
time of irradiation at 2 cm from the UV source, the amount of aggregated material 
was less, a potentially important advantage when addressing problems associated 
with sample entry in isoelectric focusing gels. Using these irradiation conditions, 
approximately 1% of membrane-bound 1 2 5 I-glucagon was incorporated into the 60 
kDa cross-linked receptor band.
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Figure 4.1 Autoradiograph Showing The Effect of UV Irradiation 
Conditions on Cross-linking of 125I-glucagon to Liver 
Plasma Membranes
Rat liver plasma membranes (400 |ig) were incubated with 1 2 5 I-glucagon 
and UV irradiated as described in section 2.2.6 under the irradiation conditions 
shown. The samples were then analysed by SDS-PAGE and autoradiography 
(2 .2 . 10).
97
kDa
170-
116-
7 6 -
6 7 -
4 3 -
3 0 -
Irradiation Conditions (distance from UV source, time of irradiation):
Lane 1: 2 cm, 5 min.
2: 2 cm, 10 min.
3: 2 cm, 20 min.
4: 2 cm, 20 min. (+ 1 |j.M unlabelled glucagon)
5: 10 cm, 5 min.
6: 10 cm, 10 min.
7: 10 cm, 20 min.
8: 10 cm, 20 min. (+1 jj.M unlabelled glucagon)
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Figure 4.2 Effect of UV Irradiation Conditions on Cross-linking of 
125I-gIucagon to Liver Plasma Membranes
Rat liver plasma membranes (400 |ig) were incubated with 1 2 5 I-glucagon 
and UV irradiated as described in section 2.2.6 under the irradiation conditions 
shown. The samples were then analysed by SDS-PAGE and autoradiography. The 
areas of the gel corresponding to the labelled 60 kDa receptor bands shown by 
autoradiography (Figure 4.1) were excised and counted for 1 2 5 I.
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4.2.1.2 Effect of Proteins and Sugars on Cross-linking
Previous work carried out in this laboratory (J.G. Beeley, unpublished 
work) had suggested that the presence of ovalbumin or BSA during the irradiation 
step of the cross-linking procedure resulted in an increase in the amount of 
membrane-bound 1 2 5 I-glucagon incorporated into the cross-linked receptor 
complex. The effect of these two proteins plus another protein, ovomucoid, and 
two sugars, GlcNAc and galactose, was investigated by incubating membranes 
with 1 2 5 I-glucagon and UV irradiating essentially as described in section 2.2.6, 
except that samples were irradiated in the presence of ovalbumin, BSA, 
ovomucoid, GlcNAc and galactose or with no additions. The samples were then 
analysed by SDS-PAGE and autoradiography (Figure 4.3). The areas of the dried 
gel corresponding to the labelled 60 kDa bands were excised and counted for 1 2 5 I. 
Figure 4.4 shows that in the presence of either ovalbumin, BSA or ovomucoid at a 
concentration of 1 mg/ml, the incorporation of membrane-bound 1 2 5 I-glucagon into 
the cross-linked 60 kDa receptor band was almost doubled while the same proteins 
at a concentration of 0 . 1  mg/ml resulted in increases in incorporation of 
approximately 20%. The presence of 0.2 M galactose or 0.2 M GlcNAc resulted in 
increases in incorporation of approximately 80% and 35% respectively. 
Determination of glucagon-binding prior to irradiation showed comparable levels of 
membrane-bound glucagon in all samples, therefore ensuring that the increases in 
incorporation seen were not due to differences in the amount of glucagon bound to 
the membranes before irradiation. Possible reasons for these results are discussed 
in section 5.2.1. However, since the | principal aim of this experiment was to 
increase the amount of 1 2 5 I-glucagon incorporated into the cross-linked 60 kDa 
receptor band, this line of investigation was not carried any further. All future 
cross-linking experiments were carried out using 1 mg/ml ovalbumin in the 
irradiation step. Under these conditions approximately 2% of membrane-bound 
1 2 5 I-glucagon was incorporated into the 60 kDa cross-linked receptor band.
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Figure 4.3 Autoradiograph Showing the Effect of Proteins and
Sugars on the Cross-linking of 125I-glucagon to Liver 
Plasma Membranes
Liver plasma membranes (400 pg) were incubated with 1 2 5 I-glucagon and 
UV irradiated as described in section 2.2.6 in the presence or absence of the 
proteins and sugars shown. The samples were then analysed by SDS-PAGE and 
autoradiography (2 .2 .1 0 ).
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Figure 4.4 Effect of Proteins and Sugars on Cross-linking of 1 2 5 I- 
glucagon to Liver Plasma M em branes
Liver plasma membranes (400 |ig) were incubated with 125I-glucagon and 
UV irradiated as described in section 2.2.6 in the presence or absence o f the 
proteins and sugars shown. The samples were then analysed by SDS-PAGE and 
autoradiography (2.2.10) and the areas of the gel corresponding to the 60 kDa 
receptor bands shown by autoradiography (Figure 4.3) were excised and counted 
for 125I.
103
4 .2 .2  Partial Purification of Cross-linked Receptor By WGA-
agarose Chromatography
Before application onto isoelectric focusing gels, cross-linked membrane 
samples were chromatographed on WGA-agarose. This was done not only to 
partially purify the covalently-labelled receptor but also to minimise interference 
from free 1 2 5 I-glucagon on isoelectric focusing gels by removing non-covalently 
bound hormone from the sample (further removal was achieved in subsequent 
concentration or precipitation steps).
Cross-linked membrane samples were solubilised in 1% Lubrol-PX as 
described in section 2.2.7. Solubilised samples were then run on 1 ml WGA- 
agarose columns as described in section 2.2.8. A typical elution profile (Figure 4.5) 
shows that most of the counts, representing free 1 2 5 I-glucagon, were eluted in the 
flowthrough while cross-linked glucagon-receptor complexes eluted as a small peak 
after the introduction of 0.5 M GlcNAc to the elution buffer. These peak fractions 
were pooled and the proteins present were precipitated as described in section 2.2.9 
and analysed by SDS-PAGE and autoradiography (2.2.10). Figure 4.6 shows the 
presence of a labelled band of approximately 60 kDa, confirming that the labelled 
GlcNAc-eluted material represented the covalently labelled glucagon receptor. The 
absence of free 1 2 5 I-glucagon in this lane demonstrates the effectivity of WGA- 
agarose chromatography followed by chloroform/methanol precipitation as a 
method for the removal of non-covalently bound labelled glucagon from the 
sample. When the flowthrough fractions shown in Figure 4.6 were pooled, 
precipitated and analysed by SDS-PAGE and autoradiography, no covalently 
labelled material was seen, indicating only one receptor population.
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Figure 4.5 WGA-agarose Chromatography of Covalently Labelled 
Receptor
Covalently labelled liver plasma membranes (400 jig) were solubilised in 
1% (w/v) Lubrol-PX (2.2.7) and run on a 1 ml WGA-agarose column as described 
in section 2.2.8. A typical elution profile is shown. The vertical arrow denotes the 
point at which the column was eluted with 0.5 M GlcNAc.
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Figure 4.6 SDS-PAGE of Covalently Labelled Receptor Following 
W GA-agarose C hrom atography
Covalently labelled liver plasma membranes (400 }ig) were solubilised in 
1% (w/v) Lubrol-PX (2.2.7) and run on a 1 ml W GA-agarose column as described 
in section 2.2.8. The GlcNAc-eluted fractions containing labelled material (Figure 
4.5) were pooled and precipitated as described in section 2.2.9 then analysed by 
SDS-PAGE and autoradiography (2.2.10).
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4 .2 .3 Isoelectric Focusing on Immobilised pH Gradients
Immobilised pH gradients (IPGs) offer considerable advantages over 
traditional carrier ampholyte (CA) gels for isoelectric focusing in that the pH 
gradient is stable with time, due to the covalent anchoring of the pH gradient to a 
polymer matrix, resulting in greatly improved reproducibility of IEF patterns. For 
isoelectric focusing of covalently cross-linked glucagon receptor, pH 4-7 IPGs 
were used. These were obtained in ready-made dry form from Pharmacia-LKB and 
allow entry of molecules with molecular weights up to 500 kDa. Although work 
described earlier in this thesis (3.3) has shown that the glucagon receptor exists in 
CHAPS predominantly in a highly aggregated form with a molecular weight of 
greater than 2 x 106  Da, Herberg et al. (1984) reported a molecular weight of 119 
kDa for the Lubrol-solubilised covalently-labelled receptor, well below the cut-off 
point for entry into the IPGs used.
4 . 2 . 3 . 1  Optimisation of Isoelectric Focusing of Solubilised 
Plasma Membranes on pH 4-7 IPGs
Initial experiments were carried out to optimise the procedure by improving 
sample entry and band resolution. These experiments were done using untreated 
plasma membranes which were solubilised with Lubrol-PX in the same way as 
described for cross-linked membranes (2.2.7). Solubilised samples were then 
concentrated to -50  pi and urea and Ampholine pH 3.5-10 were added to final 
concentrations of 6  M and 2% (w/v) respectively. Samples (10 pi) were applied to 
pH 4-7 IPG strips which had been rehydrated as described in section 2.2.11.1, 
using 6  M urea, 20% (w/v) glycerol, 0.5% (w/v) Ampholine and 2% (w/v) Lubrol- 
PX. Focusing was initially carried out at low voltage (300-500 V for 1 hour) as this 
has been shown to improve sample entiy (Gorg et al., 1988). Thereafter the voltage 
was increased to 3000 V and focusing was continued as described in section
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2.2.11.3. After focusing, the gel strips were silver stained (2.2.11.5). Stained gels 
routinely showed some unfocused material at and around the point of sample 
application, with resolution of some bands away from this point over the rest of the 
length of the gel strip (Figure 4.7). This indicated that while some of the material in 
the sample was able to enter the gel and focus, much of the material was either 
unable to enter the gel or, once entered, precipitated at or near the point of entry.
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Figure 4.7 Isoelectric Focusing of Liver Plasma M embranes on a 
pH 4-7 IPG
A sam ple o f L ubrol-solubilised  liver plasm a m em branes (2.2.11.2) 
containing 6 M urea and 2% (w/v) Ampholine pH 3.5-10 (10 |il containing -1 0  jig 
protein) was run (2.2.11.3) on a pH 4-7 IPG which had been rehydrated as 
described in section 2.2.11.1 using 8 M urea containing 0.5% (w/v) Ampholine pH
3.5-10, 20% (w/v) glycerol and 2% (w/v) Lubrol-PX. After focusing, the gel was 
silver stained using the procedure described in section 2.2.11.5.
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Extensive studies were undertaken to try to increase the proportion of sample 
entering the gel and focusing into clearly resolved bands. However, it was found 
that no improvement was made by increasing the concentration of Ampholine to 4% 
(w/v) in either the rehydration solution or the sample, contrary to the findings of 
Rimpilainen and Righetti (1985), or by replacing Lubrol-PX with NP-40. 
Similarly, it was found that neither the position nor the method of sample 
application had an effect on focusing. Hence no significant improvement in sample 
entry and band resolution could be made on that shown in Figure 4.7. 
Nevertheless, samples of partially purified covalently labelled glucagon receptor 
were run on IPGs as described below.
4 . 2 . 3 . 2  Isoelectric Focusing of Covalently Labelled Glucagon 
Receptor on pH 4-7 IPGs
IPGs were rehydrated as described in section 2.2.11.1 using 6  M urea, 
20% (w/v) glycerol, 4 % (w/v) Ampholine pH 3.5-10 and 2% (w/v) Lubrol-PX. 
Samples of partially purified covalently labelled receptor (4.2.2) were prepared for 
focusing as described in section 2.2.11.2 with urea and Ampholine at final 
concentrations of 6  M and 4% (w/v). 1 2 5 I-glucagon was prepared for focusing by 
taking up in 25 mM HEPES, pH 8.0, containing 2% (w/v) Lubrol-PX, 6  M urea 
and 4% (w/v) Ampholine pH 3.5-10. Samples (10 pi) were applied on sample 
application pieces which had been placed on the IPG strips approximately 2 cm 
from the anode. Focusing was then carried out as described in section 2.2.11.3. 
After focusing, the strips were air-dried and subjected to autoradiography. Figure 
4.8 shows that the sample containing 1 2 5 I-glucagon focused into three distinct 
bands well away from the sample application point whereas the sample containing 
covalently labelled receptor resulted in all labelled material remaining at the point of 
sample application. The difference in the behaviour of these two samples indicates 
that the failure of covalently labelled receptor to enter the gel and focus may have
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been due to the presence of receptor aggregates and these aggregates hindering the 
entry o f less aggregated species into the gel, as discussed in section 5.2.1. 
Therefore the use o f IPGs was discontinued and focusing was attem pted using 
agarose gels.
I l l
+Figure 4.8 Isoelectric Focusing of Covalently Labelled Receptor on 
a pH 4-7 IPG
IPGs were rehydrated as described in section 2.2.11.1 using 6 M urea, 
20% (w/v) glycerol, 4 % (w/v) Ampholine pH 3.5-10 and 2% (w/v) Lubrol-PX. 
The following samples were then applied to the strips:
Lane 1 - Partially purified covalently labelled glucagon receptor, i.e.
GlcNAc-eluted fractions from WGA-agarose chromatography 
(section 4.2.2) prepared as described in section 2.2.11.2.
Lane 2 - 125I-glucagon in 25 mM HEPES, pH 8.0, containing 1% (w/v)
Lubrol-PX
Both samples contained 6 M urea and 4% (w/v) Ampholine pH 3.5-10. Focusing 
was carried out as described in section 2.2.11.3. After focusing, the strips were air- 
dried and subjected to autoradiography.
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4 . 2 . 4 Isoelectric Focusing on Agarose IEF Gels
It was shown in section 4.2.3.2 that while focusing of some components of 
samples of Lubrol-solubilised plasma membranes on pH 4-7 IPGs was achieved, 
focusing of covalently labelled glucagon receptor was unsuccessful, probably due 
to problems with sample entry. Therefore, focusing was carried out on agarose 
gels. These gels have a larger pore size than the IPGs used and so will facilitate the 
entry of larger molecules.
4 . 2 . 4 . 1  Optimisation of Isoelectric Focusing of Solubilised 
Plasma Membranes on Agarose IEF Gels
Initial experiments were carried out using 1% (w/v) agarose gels containing 
3% (w/v) Ampholine pH 3.5-10 and 2% (v/v) Lubrol-PX. However, when 
samples of Lubrol-solubilised untreated membranes were applied to these gels and 
focusing was carried out, it was found that all stained material remained at the site 
of sample application, regardless of the position on the gel. Therefore, gels 
containing urea were prepared using a modification of the method of Olsson and 
L&&s (1981) as described in section 2.2.12.1. Due to the greatly reduced mechanical 
stability of agarose gels prepared in the presence of urea, it was necessary to 
increase the agarose concentration to 2% (w/v). The addition of sorbitol to the gel 
solution also provided the gel with greater stability. However, although Olsson and 
L&&s (1981) reported the use of 2% agarose gels containing 8  M urea, it was found 
that using urea concentrations above 6  M led to the gel breaking up upon opening 
the casting mould. Therefore, all gels contained 6  M urea.
Samples of Lubrol-solubilised plasma membranes were prepared as 
described in section 2.2.12.2, using final concentrations of urea and Ampholine pH
3.5-10 of 6  M and 2% (w/v) respectively, and run on a 2% (w/v) agarose IEF gel
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which had been prepared as described in section 2.2.12.1. Samples were applied to 
the gel on sample application pieces which had been placed on the gel at different 
positions. Focusing was carried out as described in section 2.2.12.3 and the gel 
was Coomassie stained (2.2.12.4). Figure 4.9 shows that focusing of components 
into distinct bands was only achieved when the sample was applied near the anode. 
Application at other positions resulted in most stained material remaining at or near 
the anodic side of the application point while material which did enter the gel failed 
to focus, with considerable streaking of material toward the anode. However, even 
when the sample was applied near the anode there was some stained material 
remaining at the anodic side of the application point and band resolution in the area 
immediately adjacent to the cathodic side was poor. It was considered that possible 
contamination of membranes with ribosomes (Evans, 1978) might lead to the 
presence of RNA-protein aggregates after solubilisation which could migrate to the 
anodic side of the sample application piece but fail to enter the gel, thus giving rise 
to the patterns shown in Figure 4.9. However, treatment of membranes with 
RNAase at concentrations of 10 |ig/ml and 50 |ig/ml had no effect on the 
electrofocusing patterns observed.
Attempts were made to reduce the amount of material remaining at the 
sample application point and to increase the resolution of the focused bands. The 
addition of SDS to the sample, as described by Schmidt-Ullrich and Wallach 
(1977), or the solubilisation of membranes with NP-40 or CHAPS instead of 
Lubrol-PX afforded no improvement. The effects of increasing the concentration of 
Ampholine pH 3.5-10 in the sample to 6% (w/v), and the effects of solubilising 
membranes in the presence of 6 % (w/v) Ampholine or 6  M urea and 6% (w/v) 
Ampholine are shown in Figure 4.10. This shows that the addition of 6% (w/v) 
Ampholine to the sample after solubilisation or the inclusion of 6 % (w/v) 
Ampholine in the solubilisation buffer resulted in a decrease in the amount of 
material remaining at the application point and better band resolution with less 
streaking. However, surprisingly, the inclusion of 6  M urea in the solubilisation
114
+Figure 4.9 Effect of Sample Application Position on Isoelectric 
Focusing of Liver Plasma M embranes on Agarose IEF 
G els
Lubrol-solubilised (2.2.7) liver plasma membranes containing 6 M urea and 
2% (w/v) Ampholine pH 3.5-10 (20 pi containing -5 0  jig protein) were applied at 
three different positions on a 2% (w/v) agarose IEF gel which had been prepared as 
described in section 2.2.12.1. Focusing was carried out as described in section 
2.2.12.3 and the focused gels were Coomassie stained (2.2.12.4).
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Figure 4.10 Effect of Ampholine and Urea on Isoelectric Focusing of 
Liver Plasma Membranes on Agarose IEF Gels
Liver plasma membranes were solubilised as described in section 2.2.7 in 
the presence or absence of 6 % (w/v) Ampholine pH 3.5-10 and 6  M urea as 
indicated. All samples contained urea at a final concentration of 6  M and Ampholine 
at a final concentration of 2% (w/v) or 6 % (w/v) as indicated. Samples (20 jj.1 
containing -50  jig protein) were applied ~1 cm from the anode of a 2% (w/v) 
agarose IEF gel which had been prepared as described in section 2.2.12.1 and 
focusing was carried out as described in section 2.2.12.3. After focusing, the gel 
was Coomassie stained (2.2.12.4).
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1 2 3 4
Lane 1: membranes solubilised in 1% (w/v) Lubrol-PX, Ampholine added
to 2% (w/v)
2: membranes solubilised in 1% (w/v) Lubrol-PX, Ampholine added
to 6% (w/v)
3: membranes solubilised in 1% (w/v) Lubrol-PX , 6% (w/v)
Ampholine
4: membranes solubilised in 1% (w/v) Lubrol-PX, 6% (w/v)
Ampholine, 6 M urea
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buffer as well as 6 % (w/v) Ampholine led to no further improvement in band 
resolution. As a result of this experiment, all further samples for electrofocusing 
were prepared with 6 % (w/v) Ampholine included in the solubilisation buffer.
In order to ensure that UV treatment of membranes did not result in an 
increase in aggregation of the membrane proteins and hence affect their behaviour 
on isoelectric focusing gels, a sample of membranes was irradiated using a 254 nm 
UV source at a distance of 10 cm from the sample for 20 minutes (i.e. the 
conditions used in the procedure for cross-linking 1 2 5 I-glucagon to membranes) 
then the sample was solubilised as described in section 2 .2 . 1 2 . 2  in the presence of 
6% (w/v) Ampholine pH 3.5-10 and run on a 2% (w/v) agarose IEF gel as 
described in section 2.2.12.3. Figure 4.11 shows that UV treatment had no effect 
on the isoelectric focusing of the membrane components.
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Figure 4.11 Effect of UV Irradiation of Liver Plasma M embranes on 
Their Isoelectric Focusing on Agarose IEF Gels
Liver plasma membranes (400 pg) were irradiated using a 254 nm UV 
source at a distance of 10 cm from the sample for 20 minutes then solubilised as 
described in section 2.2.12.2 in the presence of 6% (w/v) Ampholine pH 3.5-10 
and run on a 2% (w/v) agarose IEF gel as described in section 2.2.12.3, applying 
samples ~1 cm from the anode. A fter focusing, the gel was Coomassie stained 
(2.2.12.4).
Lane 1: untreated membranes
2: UV irradiated membranes
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4 . 2 . 4 . 2  Isoelectric Focusing of Covalently Labelled Glucagon
Receptor on Agarose IEF Gels
Following optimisation of the procedure as described in section 4.2.4.1, 
samples of covalently labelled glucagon receptor were run on agarose IEF gels. 2% 
(w/v) agarose gels were prepared as described in section 2.2.12.1. Samples of 
partially purified covalently labelled receptor (4.2.2) were prepared for focusing as 
described in section 2 .2 .1 2 .2 , solubilisation being carried out in the presence of 6 % 
(w/v) Ampholine pH 3.5-10. Focusing was then carried out as described in section
2.2.12.3, applying samples approximately 1 cm from the anode. After focusing, 
the gels were air-dried and subjected to autoradiography. However, as with IPGs 
(4.2.3.2), it was found that all labelled material in samples of covalently labelled 
receptor remained at the sample application point. This was again probably due to 
the presence of receptor aggregates failing to enter the gel and these aggregates 
hindering the entry of less aggregated species into the gel. Aggregation of the 
receptor had been observed previously in this study in different detergents (sections 
3.3.2, 4.2.1.1, 4.2.3) and is discussed further in section 5.2.1).
Due to the inability to obtain focused bands representing covalently labelled 
receptor on either IPGs or agarose IEF gels, the use of this method as a means of 
detection of phosphorylated receptor was discontinued.
120
4 .3  Thermostability of Receptor in Control and Desensitised
M embranes
A second approach used to investigate possible phosphorylation of the 
glucagon receptor during desensitisation of glucagon stimulated adenylate cyclase 
activity was to look at the thermostability of the receptor in control and desensitised 
hepatocyte membranes. The hypothesis to be tested was that phosphorylation 
would lead to a change in the thermostability of the receptor and therefore if a 
difference in the thermostability was observed, it would then be possible to 
indirectly demonstrate phosphorylation of the receptor by treating desensitised 
membranes with phosphatases and seeing a change back to the thermostability 
observed in control membranes. Similarly, control membranes could be treated with 
protein kinase C and the receptor thermostability compared with that in desensitised 
membranes.
Isolated hepatocytes from fed male Sprague-Dawley rats were prepared by 
Dr. A. Savage according to the method of Berry and Friend (1969). Desensitisation 
of glucagon-stimulated adenylate cyclase activity in intact hepatocytes was carried 
out with 10 nM vasopressin using the method of Murphy et al. (1987), again by 
Dr. A. Savage. Initially, washed crude membrane fractions were prepared from 
both control (untreated) and desensitised hepatocytes using the method of Houslay 
and Elliott (1979). However, reliable assessment of the thermostability of the 
glucagon receptor in these membrane preparations, using the procedure described in 
section 2 .2 .2 1 .2 , was not possible due to a high degree of non-specific binding 
which resulted in specific binding forming only ~20% of total binding. Therefore, 
purification of plasma membranes from both control (untreated) and desensitised 
hepatocytes was carried out as described in section 2.2.2. Due to the time involved, 
these preparations were carried out in the presence of a "phosphatase inhibitor 
cocktail" of 0.1 pM okadaic acid, 30 mM sodium pyrophosphate, 10 mM EDTA 
and 1 mM phosphoserine. Adenylate cyclase assays (Houslay et al., 1976), using
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the cyclic AMP-binding subunit of protein kinase prepared from bovine adrenal 
gland (Brown et al., 1972) to assay the cyclic AMP produced, on plasma 
membrane preparations which had been stored at -80°C demonstrated that the 
membranes from vasopressin-treated cells showed 70% of the glucagon-stimulated 
adenylate cyclase activity of membranes from control cells, this being shown by 
statistical analysis to be a significant difference. Therefore it was demonstrated that, 
after preparation and storage, membranes from vasopressin-treated cells still 
showed desensitisation of glucagon-stimulated adenylate cyclase activity compared 
with membranes from control cells.
Preliminary experiments were carried out using plasma membrane 
preparations from control cells to determine a temperature at which - 1 0 % of the 
initial specific glucagon binding activity of the membranes was present after a 
suitable time interval. This led to the adoption of 50°C as the temperature used in 
subsequent experiments. The thermostability of the receptor in these preparations 
was similar to that observed in plasma membrane preparations prepared from whole 
liver (3.3.5). Timecourses for the thermostability of the receptor in control 
membranes were carried out and desensitised membranes were carried out as 
described in section 2.2.21.2. Figure 4.12 shows that there was found to be no 
difference in the thermostability of the receptor from the two types of membrane, 
each showing a half-life of - 8  minutes at 50°C. This indicates that either i) the 
receptor is not phosphorylated during desensitisation or ii) the receptor is 
phosphorylated but that this does not bring about a change in the thermostability of 
the receptor. This is discussed in section 5.2.2. As a result, further experiments 
using phosphatases and kinases were not carried out. Therefore confirmation of 
receptor phosphorylation awaits purification of the receptor (see section 5.3).
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Figure 4.12 Thermostability of Receptor in Control and Desensitised 
Membranes
Plasma membranes were prepared as described in section 2.2.2. Samples of 
membranes (10 pg protein) were incubated at 50°C for the time intervals shown as 
described in section 2.2.21.1 and assayed for specific glucagon binding (2.2.14). 
Results are expressed as the log of the percentage of initial binding activity 
remaining after each time interval (n=3).
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4 .4  Summary
Direct cross-linking by UV irradiation of 1 2 5 I-glucagon to rat liver plasma 
membranes resulted in the identification of a specifically labelled peptide of Mr -60 
kDa. Incorporation of bound label into cross-linked material was shown to be 
increased in the presence of proteins and sugars and is discussed in section 5.2.1.
Isoelectric focusing of partially purified samples of cross-linked receptor on 
both immobilised pH gradients and IEF agarose gels resulted in labelled material 
remaining at the site of sample application, despite optimisation of both procedures 
to give good focused band patterns for solubilised membranes. The problems 
encountered in isoelectric focusing of covalently labelled receptor are discussed in 
section 5.2.1 in terms of receptor aggregation.
The thermostability of the receptor was shown to be the same in plasma 
membrane preparations from both control and desensitised cells. This result 
indicates that either (i) the receptor is not phosphorylated during desensitisation or 
(ii) the receptor is phosphorylated but that this does not result in a change in the 
thermostability of the receptor. This is discussed in section 5.2.2.
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Chapter 5 Discussion
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In this chapter an overall analysis of the results presented in Chapters three 
and four will be given and discussed in the light of previous and current work in the 
relevant areas.
5 .1  The CHAPS-solubilised Receptor
5 .1 .1  Receptor Solubilisation and Stability
Solubilisation of integral membrane proteins by detergents does not always 
simply follow the disruption of the lipid bilayer (for review see Silvius, 1992). 
Differential solubilisation of membrane proteins can arise as a result of different 
overall free energies of formation for the micelles into which they become 
incorporated, differing ease with which detergent molecules can compete with 
endogenous lipid molecules for solvation of the protein-lipid interface, and changes 
in protein-protein interactions which may influence the overall free energy of 
solubilisation.
Previous attempts to solubilise the glucagon receptor with detergents have 
usually resulted in a loss of activity, the exception being when the zwitterionic 
detergent CHAPS was used (Herberg et al., 1984). Solubilisation of active receptor 
increased greatly between 3 and 6 mM CHAPS, probably reflecting the fact that 
over this range of concentrations the critical micelle concentration of CHAPS was 
reached. However, further increasing the CHAPS concentration above 6 mM 
resulted in relatively small changes in the solubilisation of active receptor even 
though the total protein solubilised increased steadily over this range. Since the 
recovery of specific binding activity after solubilisation with 6 mM CHAPS was 
only approximately 30 % of that in membranes, the failure to see increased activity 
with CHAPS concentrations above 6 mM could not be due to complete 
solubilisation of active receptor at these concentrations. It is possible that at CHAPS 
concentrations above 6 mM there was no further solubilisation of receptor.
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However, it is also possible that further solubilisation of the receptor did occur at 
higher CHAPS concentrations but that the receptor solubilised at these 
concentrations lost activity, a proportion of which was not recovered on dilution of 
the CHAPS to 3 mM for assay. Indeed, assays of liver plasma membranes 
solubilised at CHAPS concentrations of 6 mM and above, without dilution to 3 mM 
CHAPS prior to assay, showed total abolition of specific glucagon binding activity. 
This suggests that at CHAPS concentrations at or above 6 mM conformational 
denaturation of the receptor occurs which is partially reversible upon dilution of 
CHAPS to 3 mM, although this result could also be due to the failure of the 
solubilised receptor assay at CHAPS concentrations above 3 mM. The ratio of 
detergent to lipid in the protein-containing micelle is often critical (Lund et al., 
1989) and in the case of the glucagon receptor it is likely that increasing CHAPS 
concentration leads to progressive removal of residual lipid from the protein and 
subsequent inactivation. That reversible changes in receptor conformation occur 
upon the addition of CHAPS is supported by the observation of McVittie and Gurd
(1989) that previously solubilised inactive receptors can be activated by the addition 
of Hanks' balanced salt solution. The observation of reduced thermostability of the 
CHAPS-solubilised receptor compared with that of the membrane-bound receptor 
(see section 5.1.2) provides further evidence of conformational changes in the 
receptor upon solubilisation. Another possibility is that at CHAPS concentrations of 
6 mM and above, dissociation of Gs from the receptor occurs, thus reducing the 
receptor binding affinity, and that upon dilution of CHAPS to 3 mM, 
"reconstitution" of Gs with the receptor takes place, thus restoring higher affinity 
binding. However, if this was the case, a reduction in binding similar to that given 
by the GTP-induced dissociation of Gs in membranes (50-60%) might be expected, 
whereas total abolition of binding was in fact observed. Also, solubilised receptor 
preparations assayed at 3mM CHAPS showed no sensitivity to guanine 
nucleotides, indicating the absence of functional interaction of the receptor with Gs, 
and thus precluding the possibility of "reconstitution" of dissociated G protein upon
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dilution of CHAPS. The question of interaction of Gs with the CHAPS-solubilised 
receptor is addressed in greater detail in section 5.1.2. The failure to observe 
specific glucagon binding upon assay at higher concentrations of CHAPS could 
also reflect the loss of required conformational features of glucagon itself at these 
concentrations.
The instability of the CHAPS-solubilised receptor during storage provides 
further evidence that receptor-micelle interactions provided by CHAPS do not 
replace the receptor-membrane interactions required for stable binding activity 
(McVittie and Gurd, 1989). Perturbations of the conformational stability of 
membrane proteins by detergents can arise as a result of changes in the 
environmental fluidity upon incorporation of the protein into micelles (Milder et al., 
1991), binding of detergent to the protein at sites not normally occupied by lipid 
(Simmonds et al., 1982) or displacement from the protein surface of lipids needed 
to stabilise the protein structure (Robinson et al., 1980). Changes in protein-protein 
interactions may also lead to instability after solubilisation. However, it was shown 
(section 3.2.2) that the observed instability of the receptor in CHAPS extract is due 
in part to the action of endogenous proteases. The small increase in stability brought 
about by the removal of calcium from the solubilisation buffer suggests that the 
solubilised receptor may be a target for calcium-dependent and/or calcium-stabilised 
proteases. The addition of PMSF to a mixture of protease inhibitors used by 
McVittie and Gurd (1989) resulted in almost a halving of the activity lost after 
storage for 24 hours at 4°C, suggesting significant action of serine proteases on the 
receptor in CHAPS extract. It is possible that solubilisation of the receptor by 
CHAPS increases the likelihood of proteolysis by exposing proteolytically sensitive 
regions of its structure.
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5.1.2 C haracterisation  of the CHAPS-solubilised Receptor
Characterisation of the CHAPS-solubilised receptor by sucrose density 
gradient centrifugation and gel filtration on Sepharose CL-6B (section 3.3) showed 
that the receptor exists in CHAPS extract predominantly in a highly aggregated 
state, with a small proportion of the total receptor population existing in a series of 
less aggregated forms. The relative proportions of receptor activity (-70%) and total 
solubilised protein (-25%) eluted in the void volume of gel filtration experiments 
suggest that the aggregation is to some degree specific; i.e. that the high molecular 
weight aggregates are a result of self-aggregation of the glucagon receptor or 
aggregation between the receptor and other specific proteins, rather than general 
non-specific aggregation or "incomplete" solubilisation of the membranes. The 
occurrence of the receptor in the membrane as part of a multimeric complex of 
proteins has been suggested previously (Schlegel et al., 1979), although Houslay et 
al. (1977), using the same technique of target size analysis, suggested that the 
receptor is an independent mobile species in the membrane. The identification of 
other possible proteins which may specifically aggregate with the glucagon receptor 
on solubilisation is outside the scope of this study.
Aggregation of proteins following removal of detergent from solubilised 
membranes has been observed (Valpuesta et al., 1986). However, the possibility of 
aggregation occurring only upon dilution of CHAPS extracts to a final 
concentration of 3 mM (the concentration at which sucrose density gradients and gel 
filtration were carried out) was discounted by the observation that centrifugation of 
6 mM CHAPS for 12 hours at 105 000 g results in the sedimentation of -80% of 
binding activity and the absence of any highly aggregated activity in the void 
volume of gel filtration experiments, indicating that aggregated material exists in the 
6 mM CHAPS extract. Similar results with 20 mM CHAPS extract suggest that 
aggregation is not decreased by increasing CHAPS concentration. Indeed, although 
many membrane proteins exhibit progressive deoligomerisation at increasing
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detergent concentrations or detergent:lipid ratios, some show increased aggregation 
under these circumstances, without necessarily being denatured (Silvius, 1992). 
CHAPS concentration appears to have little or no effect, however, on the 
aggregation state of the glucagon receptor over the concentration range used.
Aggregation was unaffected by increasing NaCl concentration up to a 
concentration of 1 M, suggesting that electrostatic interactions do not play an 
important role in the aggregation of the CHAPS-solubilised receptor. Over this 
range of NaCl concentrations hydrophobic interactions due to decreased solvation 
of the protein would not be expected to be promoted. Therefore it is unlikely that 
increased hydrophobic interactions counteracting any reduction in electrostatic 
interactions were responsible for the failure to see a change in the aggregation state 
of the receptor upon increasing the NaCl concentration. Therefore, it is likely that 
hydrophobic rather than electrostatic interactions are involved in the mechanism of 
aggregation. However, sucrose appeared to have a small disaggregating effect by 
an as yet unknown mechanism.
Removal of highly aggregated material by centrifugation enabled the 
determination of the Stokes radius of the smallest active species present to be made. 
The use of this value together with the S value of the smallest species observed in 
sucrose density gradient centrifugation (confirmation that the smallest species from 
each method were identical by pooling of material from the density gradient and 
running on the gel filtration column, or vice versa, was not possible due to the loss 
of activity; therefore this had to be assumed) led to the calculation of a minimum 
molecular weight of ~190 kDa for the CHAPS-solubilised receptor. An assumption 
made in this calculation is that any binding of CHAPS to the receptor is insufficient 
to significantly alter the S value or Stokes radius. Although many membrane 
proteins, after solubilisation, have been shown to bind significant amounts of non­
ionic detergents, some have been shown to bind very little, e.g. glycoprotein lib 
and III of platelets (Jennings and Phillips, 1982), and indeed the glucagon receptor 
has been shown to bind no significant amount of Lubrol-PX (Herberg et al., 1984).
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Furthermore, because of the low micelle number and low molecular mass of 
CHAPS, detergent binding may be anticipated to have a relatively small effect on 
hydrodynamic measurements compared with non-ionic detergents. It was not 
possible to assess the binding of CHAPS to the receptor by the determination of the 
S value in both H2 O and D2 O since the partial specific volume of CHAPS is so 
similar to that of the globular marker proteins used that the S value would be the 
same in both solvents, using the globular marker proteins for calibration, whether 
significant amounts of CHAPS were bound to the receptor or not (Clarke, 1975).
The recent isolation of a cDNA clone for the glucagon receptor (Jelinek et 
al.f 1993; Svoboda et al., 1993) has shown that the receptor is a 485-amino acid 
protein with a predicted molecular size of 54 962 Da (see section 5.3). Treatment of 
covalently labelled receptor with Endo F has suggested that the receptor contains at 
least four N-linked glycans accounting for 18 kDa (Iyengar and Herberg, 1984) 
and, indeed, the predicted amino acid sequence of the receptor shows the presence 
of four potential N-glycosylation sites on the extracellular N-terminal domain. 
Therefore the true molecular size of the native receptor might be expected to be 
somewhat higher than the 55 kDa peptide backbone. Indeed, SDS-PAGE analysis 
of covalently labelled receptor in this study and in previous work (Iyengar and 
Herberg, 1984; Iwanij and Hur, 1985) has led to the identification of an apparent 
molecular weight of 60-63 kDa, although if N-glycans do indeed account for 18 
kDa then even this could be an underestimate of the true molecular size. Therefore, 
based on a monomer molecular weight of 60-70 kDa, it is proposed that the 190 
kDa species identified in hydrodynamic experiments represents a trimer of receptor 
subunits. The identification of a species of similar molecular weight in membranes 
by SDS-PAGE analysis (see section 5.2.1) suggests that the observed size of the 
CHAPS-solubilised receptor is not an artifact of solubilisation. Furthermore, the 
size reported here is similar to that obtained for the membrane-bound receptor using 
target size analysis (Houslay et al., 1977). However, the possibility that it 
represents a complex between the receptor and other different proteins cannot be
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ruled out. In particular, association with the stimulatory G protein remains a 
possibility. However, in agreement with the findings of Herberg et al. (1984), the 
CHAPS-solubilised receptor was shown to bind 125I-glucagon in a guanine 
nucleotide insensitive manner, compared with membranes which showed a 50-60% 
reduction in 125I-glucagon binding in the presence of GTP. Furthermore, the 
hydrodynamic experiments described here were carried out on the unoccupied 
receptor which is proposed to be "uncoupled " from the stimulatory G protein. 
Indeed, the extent of coupling of the (32-adrenergic receptor to Gs after 
solubilisation with sodium cholate has been shown to depend on the exposure of 
membranes to ligands prior to and during solubilisation, exposure to p-agonist 
prior to solubilisation resulting in increased coupling. Herberg et al. (1984) showed 
that the lack of guanine nucleotide effect in solution was not due to the functional 
absence of Gs in the CHAPS solution since it could reconstitute guanine nucleotide 
and hormonal sensitivity to cyc~ S49 cell membrane adenylate cyclase. Hence it was 
suggested that reconstitution into a lipid environment is necessary for receptor-Gs 
interactions to occur, as shown for the p2 -adrenergic receptor.
Determination of the molecular size of the receptor in other detergents has 
yielded conflicting results. Giorgio et al. (1974) showed the presence of glucagon- 
binding proteins of over 1.5 x 106 Da after treatment of labelled membranes with 
Lubrol-PX. However, Herberg etal. (1984) proposed the Lubrol-solubilised cross- 
linked receptor to be a dimer of 119 kDa which was shown not to be associated 
with the stimulatory G protein.
Thermostability studies on the CHAPS-solubilised receptor (section 3.3.5) 
suggest the presence of two receptor populations, one accounting for -75% of the 
total population and having a half-life of -9  minutes at 35°C and the other 
accounting for -25% with a half-life of -128 minutes at 35°C. However, 
corresponding experiments on liver plasma membranes show monophasic decay, 
indicating the presence of a homogeneous receptor population with a half-life of -7  
minutes at 50°C. It is possible, therefore, that the biphasic effect observed with
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CHAPS extract could be brought about by the combined effects of heat denaturation 
and increased activity of proteases, the latter not being a contributing factor in 
experiments with membranes due to the decreased susceptibility to proteolysis of 
the membrane-bound receptor. Alternatively, the relative proportions of the two 
populations suggest that they could represent the highly aggregated and less 
aggregated species observed in the molecular size determination experiments; i.e. 
that the thermolabile population represents the highly aggregated receptor while the 
thermostable population represents the less aggregated species. However, reliable 
assessment of the specific glucagon binding activity of the less aggregated material 
was not possible due to a high proportion (>80%) of non-specific binding in a 
small amount of total binding, especially after any heat treatment.
A further possibility is that the two populations of different thermostability 
represent populations of receptor which are associated with and dissociated from 
Gs, since conformational changes in the receptor brought about by interaction with 
Gs might be expected to bring about a change in the thermostability of the receptor. 
However, this is unlikely since experiments carried out in the presence of guanine 
nucleotides resulted in no change in the thermostability of the CHAPS-solubilised 
receptor, and, as described above, the receptor did not exhibit functional interaction 
with the stimulatory G protein after solubilisation.
5 .1 .3  Affinity Chromatography Using Immobilised Glucagon
Biospecific affinity chromatography is by far the most useful and 
successfully applied method for the purification of integral membrane proteins and 
has played an essential role in the purification of hormone receptors, e.g. the insulin 
receptor (Cuatrecasas, 1972). Isolation of the CHAPS-solubilised receptor was 
attempted using biospecific affinity chromatography on immobilised glucagon 
(section 3.4). The high degree of specificity afforded by this method gives it the
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potential for a substantial degree of purification in one step. This is particularly 
important for the glucagon receptor in view of its instability after solubilisation. 
Immobilised glucagon was prepared by the attachment of methionine-27 in 
glucagon to bromoacetamidoethyl-polyacrylamide. The methionine residue in 
glucagon can be modified without altering its receptor binding affinity (Coolican et 
al. 1982). The immobilised glucagon binds CHAPS-solubilised receptor 
specifically and in a manner proportional to the amount of immobilised ligand 
present. However, selective elution of receptor, either in active or inactive form, is 
not possible using the methods described here, as discussed below.
The method of choice for elution is to elute with glucagon itself as this is 
potentially a highly specific method. However, the removal of glucagon to a 
concentration at which assay for the soluble receptor can be carried out would be 
required. This proved to be highly problematical. Removal of glucagon by binding 
the glucagon-eluted receptor to WGA-agarose then washing with an adequate 
volume of buffer was unsuccessful. It was shown that solubilised receptor bound 
to WGA-agarose is lost during the course of washing with the required volume of 
buffer. This indicates that binding of the receptor to WGA-agarose in the presence 
of CHAPS is less stable than the binding of cross-linked receptor to the agglutinin 
in Lubrol-PX (see section 4.2.2). Therefore it is possible that loss of receptor 
bound to WGA-agarose after elution was the reason for the inability to detect 
receptor using this procedure; alternatively, it may have been due to failure to elute 
the receptor from glucagon-P150. Similarly, attempts to remove glucagon by 
passing glucagon-eluted material through dextran-coated charcoal columns failed to 
yield active receptor, due either to loss of activity through this procedure or to 
failure to elute receptor from glucagon-P150. This was tested by elution of 
glucagon-P 150-receptor complexes with glucagon and analysis of the eluate by 
SDS-PAGE and showed, as far as the sensitivity of the silver staining procedure 
allows, that no receptor is eluted even after incubation with 100 |iM glucagon for 
20 hours. With CHAPS extract containing at least 200 fmol receptor/mg soluble
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protein (McVittie and Gurd, 1989) it is calculated that the starting material in a 
typical affinity chromatography experiment described here contains approximately 
10 ng receptor. Since the silver staining procedure used is capable of detecting as 
little as 0.1-1.0 ng of polypeptide in a single band (Sambrook et al., 1989), elution 
of less than 10% of bound activity (assuming 100% of applied activity binds) 
should still be readily detectable. Hence it appears that the receptor binds to the 
immobilised ligand with very high affinity. If the affinity of the complex is very 
high, the time required for complete dissociation may be quite appreciable, even 
with high concentrations of competing ligand in the elution buffer. If this is indeed 
a problem, it could possibly be overcome by modification of the immobilised ligand 
to reduce its affinity, as has been shown in the use of immobilised glucagon in the 
purification of anti-glucagon antibodies (Murphy, 1974). An alternative approach to 
reducing the affinity to the immobilised ligand would be to increase or decrease 
(depending on the relative importance of ionic and hydrophobic interactions) the salt 
concentration in the binding buffer but this could also decrease the subsequent 
interaction with free ligand in affinity elution (Dean et al., 1985).
Elution of the receptor with urea was considered a feasible procedure from 
the finding that inactivation of CHAPS-solubilised receptor binding activity after 
treatment with 2 M urea is partially reversible after overnight dialysis. Therefore the 
failure to recover active receptor after elution of glucagon-P 150-receptor complexes 
with 2 M urea followed by overnight dialysis was surprising. Whilst inactivation by 
urea during elution and subsequent failure to recover activity after dialysis is 
possible, the preliminary experiments described above showed this not to be the 
case when treating CHAPS extract with 2 M urea, and it seems more likely that the 
receptor was not eluted by 2 M urea. Similarly, when elution was carried out with 
pH 4 or pH 5 buffers there was no recovery of activity. Since great care was taken 
to ensure that the eluates were adjusted back to pH 7.5 as quickly as possible, it 
again seems more likely that failure to recover activity was due to the absence of 
elution of the receptor rather than any inactivation during elution.
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Elution of glucagon-P 150-receptor complex with SDS followed by analysis 
on SDS-PAGE shows that a small amount of the majority of the proteins originally 
present in CHAPS extract bind to glucagon-P 150. These proteins were also seen 
after SDS elution of bromoacetyl-P150 which has been incubated with CHAPS 
extract and therefore probably represent proteins which bound non-specifically to 
the acrylamide derivative support material. The absence of significant amounts of 
protein in a high salt wash of glucagon-P 150-receptor complexes indicates that this 
non-specific binding arises as a result of hydrophobic interactions.
5 .2  Receptor Desensitisation and Phosphorylation
5 . 2 . 1  Photoaffinity Labelling and Isoelectric Focusing of
Glucagon Receptor
Direct cross-linking of 125I-glucagon to its receptor by UV irradiation leads 
to the identification of a specifically labelled glucagon-receptor complex of Mr -60 
lOOO, correlating well with the results obtained by Iwanij and Hur (1985) using a 
similar procedure. The presence of labelled material of higher molecular weight, 
including material which is too large to enter the stacking gel, again demonstrates 
aggregation of the receptor, here occurring even in the presence of SDS. The 
observation of a labelled band of molecular weight -170 kDa indicates a trimeric 
aggregate of the receptor, as seen in the CHAPS-solubilised state (see section 
5.1.2), although there is no evidence of the putative receptor dimer observed by 
Herberg et al. (1984) and Iwanij and Hur (1985).
The increase in the incorporation of membrane-bound 125I-glucagon into the 
cross-linked receptor band in the presence of added proteins is surprising. The most 
likely explanation of this effect is that the presence of additional protein during the 
irradiation step protects the receptor from UV-promoted degradation. However, it is
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questionable whether this explanation could also account for the observation of a 
smaller increase in cross-linking in the presence of sugars. A reduction in non­
specific binding of 125I-glucagon to the tube surface can be discounted since the 
proteins and sugars were added only during the cross-linking step, and the amount 
of specific binding of 125I-glucagon to the receptor was shown to be the same for 
each sample prior to irradiation. The nature of this effect merits further 
investigation; however, since the main purpose here was to increase the amount of 
incorporation of bound label into cross-linked label, no further investigation was 
carried out
Partial purification of cross-linked receptor was carried out by WGA- 
agarose chromatography. The absence of any labelled material in the flowthrough 
indicates that, in terms of binding to wheat germ agglutinin, there is only one 
receptor population. This is in agreement with Herberg et al. (1984), who found no 
labelled receptor remaining in solution after exposure to wheat germ agglutinin- 
Sepharose, but in contrast to the findings of Iwanij and Vincent (1990) who found 
separate populations of covalently labelled receptor that bound or did not bind to the 
agglutinin. However, Mason and Tager (1985), using digitonin-solubilised non­
cross-linked glucagon-receptor complexes, showed that high affinity receptors bind 
to wheat germ agglutinin whereas low affinity receptors do not bind. This might 
indicate that differential glycosylation could alter receptor affinity. Hence it is 
possible that using the cross-linking procedure described here only high affinity 
glucagon-receptor complexes underwent covalent cross-linking and this is why all 
covalently labelled material was seen to bind to wheat germ agglutinin.
Isoelectric focusing of covalently labelled glucagon receptor gives further 
demonstration of the tendency of the receptor to form large aggregates. Early 
problems encountered in the isoelectric focusing of membrane proteins in 
immobilised pH gradients (poor sample entry, smearing and lack of sharply 
focused bands) were overcome by the addition of carrier ampholytes to both the gel 
and the solubilised protein sample (Rimpilainen and Righetti, 1988). The
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subsequent improvement in focusing given by this procedure was proposed to arise 
as a result of the formation of detergent-carrier ampholyte mixed micelles which 
greatly improve the solubility of the membrane proteins under study. However, 
here it is shown that even after such treatment of samples of partially purified 
covalently labelled glucagon receptor and the inclusion of carrier ampholyte in the 
gel rehydration solution, all labelled material remains at the point of sample 
application. Since 125I-glucagon focuses into distinct bands under the same 
conditions it appears that the inability of the glucagon receptor to focus is due to the 
presence of receptor aggregates. These aggregates may be too large to enter the gel 
matrix and exacerbate the problem by clogging the gel surface and hindering the 
entry of less aggregated forms of the receptor into the gel (Gorg et al., 1988). This 
problem is perhaps not surprising in view of the observations that some labelled 
material does not enter the stacking gel on SDS-PAGE under conditions where 
aggregation may be expected to present less of a problem, and that in the CHAPS- 
solubilised state a large proportion of the receptor activity is in a form over 2 x 106 
Da, well over the exclusion limit for IPGs. Similarly, using larger pore size agarose 
IEF gels, even after extensive optimisation of the procedure so that good resolution 
of the components of solubilised membrane preparations was achieved, all labelled 
material in samples of covalently labelled receptor remain at the sample application 
point, presumably due to the same reasons as described for IPGs. In view of the 
reported molecular weight of 119 kDa for the Lubrol-solubilised cross-linked 
receptor by Herberg et al. (1984), the problems described above may seem 
surprising. However, it should be pointed out that their gel filtration profile did not 
show whether aggregated labelled material was eluted at or near the void volume; in 
view of the results of SDS-PAGE it is likely that this material did exist. Indeed 
earlier work showed the presence of glucagon-binding proteins of over 1.5 x 106 
Da after treatment of labelled membranes with Lubrol-PX (Giorgio et al., 1974).
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5 .2 .2  Therm ostability of Receptor in Control and Desensitised
Membranes
For many proteins, the biologically active conformation is only marginally 
more stable than unfolded, inactive conformations. The effect of temperature on the 
stability of proteins is a result of changes in the free energy of the protein. This in 
turn is determined by the enthalpy change for unfolding and the difference in heat 
capacity between the unfolded and folded conformations (Pace, 1990). Hence the 
stability of a protein at a certain temperature gives an indication of the degree of 
unfolding shown by that protein at that temperature. Here it was proposed that 
phosphorylation of the glucagon receptor might result in a change in its 
conformation which in turn could alter the tendency of the receptor to unfold at 
higher temperature. Hence the thermostability of the phosphorylated receptor, as 
determined by glucagon binding, might be expected to differ from that of the 
unphosphorylated receptor.
The thermostability of the glucagon receptor was found to be the same in 
plasma membranes preparations from both control and vasopressin-desensitised 
cells. The presence of a "phosphatase inhibitor cocktail" during membrane 
preparation and the subsequent demonstration that membranes prepared from 
desensitised cells still showed desensitisation of glucagon-stimulated adenylate 
cyclase activity compared with membranes prepared from control cells, allows the 
possibility of dephosphorylation of receptor during membrane preparation to be 
discounted. Therefore the failure to observe any change in thermostability indicates 
that either (i) the receptor is not phosphorylated during desensitisation or (ii) the 
receptor is phosphorylated but that this does not result in a change in the 
thermostability of the receptor. Of these two possibilities the second seems to be the 
more likely. Phosphorylation of the (^-adrenergic receptor has been shown to 
occur at sites in the third cytoplasmic loop or the C-terminal domain, regions which 
provide linear recognition sequences for coupling to Gs (Kobilka, 1992). Therefore
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it is possible that phosphorylation might affect G protein coupling without having a 
major effect on the overall conformation of the receptor which is stabilised by the 
transmembrane regions. Therefore phosphorylation, whilst altering G protein 
coupling, might not affect the thermostability of the receptor.
Recent isolation of a cDNA clone for the glucagon receptor by an 
expression cloning strategy (Jelinek et al., 1993) has shown that a sequence motif 
important for G protein coupling is situated directly next to a putative serine 
phosphorylation site, and in addition there are several other potential sites (serine 
and threonine) for phosphorylation in the carboxyl terminal domain. This suggests 
that, as expected, phosphorylation of the receptor and subsequent uncoupling from 
the stimulatory G protein may form the molecular mechanism of desensitisation of 
glucagon-stimulated adenylate cyclase. The ability of the phorbol ester TP A 
(Murphy et al., 1987) and diacylglycerol (Newlands and Houslay, 1991) to mimic 
desensitisation indicates that this phosphorylation occurs as a result of stimulation 
of protein kinase C. Indeed, the predicted amino acid sequence of the glucagon 
receptor contains a potential phosphorylation site for protein kinase C (Svoboda et 
al., 1993). It remains to be seen whether, in a situation analogous to desensitisation 
of the P2 -adrenergic receptor (Kobilka, 1992), there are also roles for protein 
kinase A and/or a glucagon receptor specific protein kinase.
5 .3  Future Prospects
The recent isolation of a cDNA clone for the glucagon receptor (Jelinek et 
al., 1993; Svoboda et al.y 1993) has shown that this receptor is a 485-amino acid 
protein with a predicted molecular size of 54 962 Da and a predicted structure 
similar to that of other G protein coupled receptors, with seven transmembrane 
domains, three extracellular and three cytoplasmic loops. The extracellular domain 
contains four potential N-linked glycosylation sites while the cytoplasmic domains
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contain, as described above, a sequence motif important for G protein coupling and 
several potential phosphorylation sites. The expression cloning strategy used 
detected only one glucagon receptor cDNA, and the expressed receptor was shown 
to increase the intracellular concentration of both cAMP and calcium, indicating that 
only one receptor is responsible for the two types of signalling observed in 
hepatocytes, as shown for the calcitonin receptor (Chabre et al., 1992). It is 
possible, therefore, that the stimulation of the two signalling pathways may be 
brought about by the coupling of two different G proteins to a single receptor 
population. However, this does not preclude the possibility of other forms of 
receptor heterogeneity, e.g. differing affinities for glucagon, arising as a result of 
differential glycosylation.
The isolation of a cDNA clone represents a major advance in the area of 
glucagon receptor research. However, the studies described in this thesis could be 
furthered by using the predicted amino acid sequence of the cloned receptor to 
generate specific peptides for the raising of monoclonal antibodies which could then 
be used for purification of the receptor. Purified receptor would enable confirmation 
to be made of phosphorylation during desensitisation of glucagon-stimulated 
adenylate cyclase, while reconstitution of the receptor in appropriate membrane 
systems with guanine nucleotide binding proteins and adenylate cyclase and/or 
phospholipase C would enable full characterisation of the active receptor and its 
mechanisms of signal transduction to be made. The availability of a cDNA clone for 
the glucagon receptor would also enable gene products resulting from site-directed 
mutagenesis to be reconstituted into such systems in order to assess the 
functionality of specific domains of the receptor.
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